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Thesis Outline  
The main goals of the present work are drawing a safety profile for Glucagon-Like Peptide-1 
receptor (GLP-1R) agonists, namely BYETTA, BYDUREON, VICTOZA, LYXUMIA, 
EPERZAN and TRULICITY (European Union’s names), and conclude about the need and/or 
opportunity of adapting the Risk Management Plan (RMP) for the new markets, taking into 
account the safety data collected both in European Union (EU) and United States of America 
(U.S.). 
 
The thesis is divided in three main parts:  
Part I consists of a general introduction organized in three subtopics, one focusing on the 
disease and its epidemiology, the second presents the therapeutic options available at the 
moment, and the third one, passing by the pharmacology and distribution of the GLP-1R, 
presents an overview of the GLP-1R agonists approved and their mode of action.  
Part II comprises the methodology and results obtained through this work, which are 
presented as a comparative analysis between data found in nonclinical and clinical 
developmental plan, which are compiled in the RMP. Additionally, it is presented a 
comparison of safety concerns considered by European Medicines Agency (EMA) and those 
ones identified by U.S. Food and Drug Administration (FDA).  
Part III presents a general discussion and the final remarks of all the results obtained 
throughout this work.  
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Abstract  
Diabetes Mellitus (DM) is one of the most 
important diseases at public health level 
around the world.  
Over the last 25 years there has been a 
dramatic increase in the number of people 
with diabetes around the world. In Portugal, 
in 2014 the estimated prevalence of 
Diabetes in population with ages between 
20 and 79 years was 13.1%, i.e. more than 
1 million of Portuguese people in this age 
range had Diabetes. During the last 
decade, in Portugal, it has been observed a 
significant decrease in the number of 
potential years of life, lost by DM. Diabetes 
assumes a preponderant role in the causes 
of death, and it was the cause of 4.0% of 
deaths occurred in 2014. 
The treatment of diabetes has come a long 
way in the last century. Starting with the 
discovery of insulin in 1921, it has seen 
also the development of antidiabetic drugs. 
In recent years, newer drugs have become 
available, targeting specific components of 
the spectrum of pathophysiologic 
abnormalities, regulating glucose input, and 
also addressing glucose utilization and 
disposal through impacts on insulin 
resistance and insulin deficiency. The 
Glucagon-Like Peptide-1 receptor (GLP-
1R) agonists mimic the GLP-1 function in 
order to enhance insulin secretion after 
food-intake, restoring the incretin function, 
while being protected from the DPP-4 
deactivation. This is achieved by binding to 
a GLP-1R that resides in the β-cell. 
This work focused on drawing a safety 
profile for GLP-1R agonists and conclude 
on the need and/or opportunity of adapting 
their Risk Management Plans (RMPs) for 
the new markets, taking into account the 
safety data collected both in EU and U.S.. 
The methodology herein used was based 
on the comparison nonclinical and clinical 
data and RMPs for each medicinal product. 
Following this, it was presented a resume 
table identifying the risks considered by 
European Medicines Agency (EMA) and 
those ones accepted by U.S. Food and 
Drug Administration (FDA). After that, a 
comparison of adverse reactions reported 
both in European Union (EU) and U.S. 
within each medicinal product was 
performed.  
It was concluded that the relevant safety 
information identified in the nonclinical 
phase was assessed and observed during 
the clinical phase. The results obtained 
from all the nonclinical and clinical studies 
were resumed in the RMP. When 
observing the post-marketing data, 
collected from the public databases of 
adverse reactions reports, it was realized 
that, although some exceptions, the risks 
identified previously were the ones mostly 
reported. In general, the safety concerns 
identified were similar to all GLP-1R 
agonists. 
Regarding the European and the U.S. data 
several discrepancies were identified, 
namely on what concerns to the 
malignancies occurrence.  
It became clear that the occurrence of 
adverse reactions was associated both to 
the pharmaceutical formulation of the 
medicinal products and to their mechanism 
of action.  
Although there are some areas of special 
concern which require further and thorough 
analysis (namely the occurrence of 
cardiovascular (CV) adverse effects and 
thyroid or pancreatic cancers), it was 
concluded that all safety concerns are very 
well monitored and followed either by the 
EMA/FDA or by the Marketing 
Authorisation Holders (MAHs).  
As final conclusion, it was clear that the 
safety profile of GLP-1R agonists remain 
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unchanged after this evaluation and no 
additional minimisation measures, other 
than those already defined and 
implemented, seem to be necessary, and, 
therefore, the RMPs do not need to be 
updated.  
 
Key words: GLP-1R agonists, BYETTA, 
VICTOZA, BYDUREON, LYXUMIA, 
ADLYXIN, EPERZAN, TANZEUM, 
TRULICITY, adverse reactions.  
 
 
Resumo 
A Diabetes Mellitus (DM) é uma das 
doenças mais importantes para a saúde a 
nível mundial.  
Durante os últimos 25 anos houve um 
aumento dramático no número de pessoas 
com diabetes em todo o mundo. Em 
Portugal, em 2014 a prevalência estimada 
de Diabetes na população com idades 
compreendidas entre os 20 e os 79 anos 
era de 13.1%, isto é, mais de 1 milhão de 
Portugueses nesta faixa etária tinham 
Diabetes. Durante a última década, em 
Portugal, houve uma redução significativa 
do número de anos de vida, perdidos 
devido à DM. A Diabetes assume um papel 
preponderante entre as causas de morte, 
sendo a responsável por 4% das mortes 
ocorridas em 2014. 
O tratamento da diabetes percorreu um 
longo caminho no século passado. 
Começando com a descoberta da insulina 
em 1921, tendo-se também assistido a um 
grande desenvolvimento de medicamentos 
antidiabéticos. Nos últimos anos, novos 
medicamentos ficaram disponíveis, cujos 
alvos são componentes específicos do 
espectro das deficiências fisiopatológicas, 
regulando a entrada de glicose e também a 
utilização e eliminação de glicose através 
de ações na resistência à insulina e 
deficiência de insulina. Os agonistas do 
recetor do peptídeo-1 semelhantes ao 
glucagon (GLP-1R) imitam a função do 
GLP-1 de modo a aumentar a secreção de 
insulina após a ingestão de alimentos, 
restaurando a função incretina, enquanto 
são simultaneamente protegidos da 
desativação pelo DPP-4. Esta ação é 
alcançada pela sua ligação ao GLP-1R que 
se encontra na célula β.  
Este trabalho focou-se no desenho de um 
perfil de segurança para os agonistas do 
GLP-1R com vista a apurar a necessidade 
de adaptação dos Planos de Gestão de 
Risco (RMPs) aos novos mercados, tendo 
em conta os dados de segurança 
recolhidos na Europa (EU) e nos Estados 
Unidos (U.S.).  
A metodologia utilizada baseou-se na 
comparação dos dados não-clínicos e 
clínicos com os RMPs para cada 
medicamento. Apresentou-se em formato 
tabelar um resumo dos riscos 
considerados pela Agência Europeia do 
Medicamento (EMA) e os riscos aceites 
pela U.S. Food and Drug Administration 
(FDA). Após esta abordagem, foi realizada 
uma comparação entre as reações 
adversas reportadas na EU e nos U.S. 
para cada um dos medicamentos. 
Concluiu-se que a informação de 
segurança relevante identificada na fase 
não-clínica foi avaliada e observada 
durante a fase clínica. Os resultados 
obtidos nos estudos não-clínicos e clínicos 
foram resumidos no RMP. Pela 
observação dos dados pós-marketing, 
obtidos a partir das bases de dados 
públicas de notificações de reações 
adversas, concluiu-se que, apesar de 
algumas exceções, os riscos identificados 
anteriormente são os mais reportados. Em 
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geral, os problemas de segurança 
identificados são semelhantes para todos 
os agonistas GLP-1R.  
Relativamente aos dados da EU e dos 
U.S., várias discrepâncias foram 
detetadas, nomeadamente no que se 
refere à ocorrência de tumores.  
Tornou-se evidente que a ocorrência de 
reações adversas está dependente quer da 
forma farmacêutica dos medicamentos 
quer do mecanismo de ação dos mesmos.  
Embora existam várias áreas de especial 
atenção que requerem mais e minuciosa 
análise (nomeadamente a ocorrência de 
efeitos adversos cardiovasculares (CV) e 
de cancros da tiroide e pancreáticos), 
considera-se que todos os problemas de 
segurança estão bem monitorizados e 
seguidos tanto pela EMA/FDA como pelos 
titulares de autorização de introdução no 
mercado (MAHs).  
Como conclusão, percebeu-se que o perfil 
de segurança dos agonistas GLP-1R 
permaneceu inalterado após esta 
avaliação. Deste modo, não parece ser 
necessário propor novas medidas de 
minimização de risco, para além das já 
definidas e implementadas, pelo que não é 
necessário atualizar os RMPs.  
 
Palavras-chave: Agonistas GLP-1R, 
BYETTA, VICTOZA, BYDUREON, 
LYXUMIA, ADLYXIN, EPERZAN, 
TANZEUM, TRULICITY, reações adversas.  
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INTRODUCTION 
I. Diabetes 
Diabetes Mellitus (DM) is one of the most important diseases at public health level around 
the world, as it is one of the most common no transmissible disease and it could lead to the 
development of diverse and severe chronic complications.  
Over the last 25 years there has been a dramatic increase in the number of people with 
diabetes around the world [1]. 
According to Beaser [2], over 21 million people in U.S. have DM, and this number continues 
to increase at the rate of about 1 million new patients diagnosed every year. Diabetes hits 
every age, ethnicity, and socioeconomic status.  
According to International Diabetes Federation (2009), the worldwide prevalence for diabetes 
in 2010 was 285 million, which represented 6.4% of adult worldwide population; the same 
organization foresees that 438 million people worldwide will be suffering from this disease in 
2030.  
A study performed in United Kingdom, based on The Health Improvement Network (THIN) 
data, revealed that between 1996 and 2005 the prevalence of diabetes increased from 2.8% 
to 4.3% and incidence also increased from 2.7 per 1000 people-year to 4.42 per 1000 
people-year [3]. 
In 2014, 9% of adults 18 years and older had diabetes. In 2012 diabetes was the direct 
cause of 1.5 million deaths. More than 80% of diabetes deaths occur in low- and middle-
income countries [4]. According to data presented by World Health Organization (WHO), the 
prevalence of diabetes in 2000 was about 171,000,000 and it is estimated to be around 
366,000,000 in 2030 [5]. 
Diabetes remains the leading cause of blindness and renal failure in U.S. and its total 
number of cases continues to increase. In addition, diabetes is associated with neuropathy, 
vascular disease leading to amputation, and markedly increases the risk of heart disease, 
birth defects and other serious problems. The WHO has predicted a worldwide epidemic of 
diabetes over the next 25 years that will strike even harder at less-developed countries as 
they become more westernized [2]. 
It is estimated that in 2014 there were 382 million people with diabetes and that in 2035 this 
value will increase to 592 million. The number of people with type 2 diabetes is increasing in 
all countries. The biggest portion of people with type 2 diabetes has ages comprised 
between 40 and 59 years of age. There are 179 million people with diabetes who do not 
know they have the disease. Diabetes led to 4.9 million deaths in 2014 [6]. 
In Portugal, in 2014 the estimated prevalence of Diabetes in population with ages between 
20 and 79 years (7.8 million of individuals) was 13.1%, i.e. more than 1 million of Portuguese 
people in this age range had Diabetes. The impact of aging on the age structure of 
Portuguese population (20-79 years) was reflected in an increase of 1.4 percentage points of 
prevalence rate of Diabetes between 2009 and 2014, which corresponded to a growth of 
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about 12%. During the last decade, in Portugal, it has been observed a significant decrease 
in the number of potential years of life, lost by DM. Diabetes assumes a preponderant role in 
the causes of death, and it was the cause of 4.0% of deaths occurred in 2014 [6]. 
Diabetes is a chronic disease that occurs either when the pancreas does not produce 
enough insulin or when the body cannot effectively use the insulin it produces [4]. Diabetes is 
not a single disease, but is constituted by several complex disorders that share the major 
common features – elevated levels of glucose in the blood, abnormalities in lipid metabolism 
and increased risk for long-term micro- and macrovascular complications [2]. 
There are three main forms of diabetes, Gestational diabetes, Type 1 Diabetes Mellitus and 
Type 2 Diabetes Mellitus (T2DM). Despite a brief resume will be herein presented for the first 
two, the present work will focus on T2DM. 
Gestational diabetes is hyperglycaemia with blood glucose values above normal but below 
those diagnostic of diabetes, occurring during pregnancy. Women with gestational diabetes 
are at an increased risk of complications during pregnancy and at delivery. They are also at 
increased risk of type 2 diabetes in the future [4]. 
Type 1 diabetes is characterized by deficient insulin production and requires daily 
administration of insulin. This condition is caused by a lesion in the β-cells of the pancreas. 
However, the trigger mechanism is not known and it is not preventable with current 
knowledge [4, 7]. 
The most common form of diabetes and the major cause of the worldwide epidemic of the 
disease is T2DM. This comprises 90% of people with diabetes around the world, and is 
largely the result of excess body weight and physical inactivity. It results from the body’s 
ineffective use of insulin. The metabolic defects underlying T2DM are a triad of insulin 
resistance, β-cell dysfunction and impaired hepatic glucose production. It is driven primarily 
by insulin resistance, which can affect multiple tissues of the body and eventually lead to 
relative insulin deficiency. Insulin resistance is the pathophysiologic hallmark of this 
condition. The imbalance between energy supply and expenditure increases the 
concentration of fatty acids in the blood. This in turn reduces glucose utilization in muscle 
and fatty tissues. The result is a resistance to insulin, forcing an increase of insulin release. 
The resulting down-regulation of the receptors further raises insulin resistance. With insulin 
resistance, increased amounts of insulin may be required to achieve a given hypoglycaemic 
effect. Early in the natural history of T2DM, the pancreas may be able to produce this 
increased insulin quantity, and many people with this condition become hyperinsulinemic. 
Initially, the hyperinsulinemia may be able to compensate for the insulin resistance. Over the 
time, the numbers of β-cells often decline, and hyperinsulinemia may be insufficient to 
overcome the insulin resistance, and clinical diabetes may be diagnosed [2, 4, 7-9]. 
Until recently, this type of diabetes was seen only in adults. However, the number of T2DM 
cases is rising in children and young adults, mostly due to lifestyles changing [2, 4]. This 
condition appears to have a strong genetic component and it is found more frequently in 
certain families and ethnic minority groups, such as Hispanics, African-Americans, Pacific 
Islanders and American Indians [9]. Since the risk of long-term complications of diabetes 
increases with duration of the disease, as more and more individuals develop diabetes at 
younger and younger ages, the medical community will be faced with a rapidly growing 
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population of individuals at risk for the eye, kidney, vascular, and neurologic complications of 
diabetes [2, 4]. 
 
II. Current therapeutic options of diabetes  
The treatment of diabetes has come a long way in the last century. Starting with the 
discovery of insulin in 1921, it has seen also the development of antidiabetic drugs [2]. 
The development of oral drugs to treat T2DM has been one of the major milestones in the 
modern era of diabetes treatment. Since the 1950s, it has been possible to treat T2DM with 
tablets. In recent years, newer drugs have become available, targeting specific components 
of the spectrum of pathophysiologic abnormalities, regulating glucose input, and also 
addressing glucose utilization and disposal through impacts on insulin resistance and insulin 
deficiency [1, 2].  
The following table (Table 1) presents the currently-available glucose lowering agents 
grouped by their chemical class [1, 2, 10, 11]: 
 
 
Table 1 - Currently-available glucose lowering agents 
Class Cellular Mechanism Primary Action(s) 
Example of 
Compound(s) 
Biguanides Activates AMP-kinase 
Decrease hepatic 
glucose production 
Metformin 
Sulfonylureas (2nd 
generation) 
Closes KATP channels on β-
cell plasma membranes 
Increase insulin 
secretion 
Glyburide/ 
glibenclamide 
Glipizide 
Gliclazide 
Glimepiride 
Meglitinides 
Closes KATP channels on β-
cell plasma membranes 
Increase insulin 
secretion 
Repaglinide 
Nateglinide 
Thiazolidinediones or 
Glitazones 
Activates the nuclear 
transcription factor PPAR-γ 
Increase insulin 
sensitivity 
Pioglitazone 
Rosiglitazone 
α-Glucosidase 
inhibitors 
Inhibits intestinal α-
glucosidase 
Slows intestinal 
carbohydrate 
digestion/absorption 
Acarbose 
Miglitol 
Voglibose 
DPP-4 inhibitors 
Inhibits Dipeptidyl-
Peptidase 4 (DDP-4) 
activity, increasing 
postprandial active incretin 
(Glucagon-Like Peptide-1 
[GLP-1], glucose-
dependent insulinotropic 
polypeptide [GIP]) 
concentrations 
Increase insulin 
secretion (insulin-
dependent) 
Decrease glucagon 
secretion (glucose-
dependent) 
Sitagliptin 
Vildagliptin 
Saxagliptin 
Linagliptin 
Alogliptin 
Bile acid 
sequestrants 
Binds intestinal bile acids, 
increasing bile acid 
production 
Unknown, probably 
decrease hepatic 
glucose production 
and increase incretin 
levels 
Colesevelam 
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Insulins Activates insulin receptors 
Increase insulin 
disposal 
Decrease hepatic 
glucose production 
Human NPH 
Human regular 
Lispro 
Aspart 
Glulisine 
Glargine 
Detemir 
Premixed 
Sodium glucose co-
transporters 2 
(SGLT2) inhibitors 
Inhibit glucose re-
absorption in the proximal 
renal tubules 
Increase urinary 
glucose excretion 
Reduce glucose levels 
in blood 
Canagliflozin 
Dapagliflozin 
Empagliflozin 
 
 
III. Incretin effect 
 
 
Figure 1 – Physiological Actions of Incretins. In Dr. sherif W. Mansour Entero Insular Axis 
(http://www.slideshare.net/drsherif36/entero-insular-axis-dr-sherif-w-mansour). 
 
The existence of the incretin system has been known for a number of years, but it was not 
until recently that this knowledge has translated into a mode of treating diabetes, since 
incretin effect is significantly reduced or absent in people with T2DM. It had been observed 
for many years that when glucose was taken orally, the resulting insulin stimulatory response 
was greater than when glucose was given intravenously. This difference in response is 
referred to as the Incretin Effect. In other words, the Incretin Effect designates the 
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amplification of insulin secretion elicited by hormones from the gastrointestinal (GI) tract. It is 
primarily due to the effects of two hormones secreted from cells in the small intestine when 
food enters the stomach and which stimulate insulin secretion and glucagon suppression, 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) (Figure 1). After secreted by the GI tract during food intake, the incretin hormones link 
to the pancreatic β-cell receptor, stimulating insulin secretion in response to glucose 
absorption. As GLP-1 and GIP stimulate insulin secretion through a glucose-dependent 
mechanism, insulin is only secreted when hyperglycaemia is verified [2, 3, 7, 12-14]. Beyond 
this effect in pancreas, incretins have also effects in several other organs, for instance heart, 
kidney, liver and brain (Figure 1).  
GLP-1, a 30 amino acids peptide, is the most important incretin and its modulation has 
proven being useful in T2DM therapy. It is secreted by the L-cells in the distal small intestine 
(jejunum and ileum) upon stimulation by the presence of incoming nutrients. GLP-1 is rapidly 
metabolized by the enzyme Dipeptidyl-Peptidase 4 (DPP-4), an enzyme linked to cell 
membranes which is presented in several tissues, such as liver, kidneys, bowel, endothelial 
cells and lymphocytes, and others. Thus, GLP-1 half-life is about 4-5 minutes (Figure 2) [1, 2, 
15].  
 
Figure 2 – Action of DPP-4 enzyme on GLP-1. In Kirsten Kulasa et al., 2010 [16]. 
 
 
III. 1. GLP-1 Receptor Agonists 
i. Pharmacology and distribution of the GLP-1R 
G protein-coupled receptors (GPCRs) constitute a large family of receptors that sense 
molecules outside the cell and activate inside signal transduction pathways and cellular 
responses [17].  
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Most of the effects of GLP-1, such as improvement of glycaemic control, are mediated by 
direct interaction with GLP-1R on specific tissues, for instance in pancreas the increasing 
insulin release and decreasing glucagon release, in the brain the decreasing appetite and in 
the stomach the delayed gastric emptying and decreasing appetite as well (Figure 1). 
However, the actions of GLP-1 in liver, fat, and muscle most likely occur through indirect 
mechanisms. GLP1 receptor activation directly promotes cell proliferation and enhances cell 
survival in several tissues including β-cells, neurons, fibroblasts, cardiomyocytes and thyroid 
C-cells [1, 12, 14, 15, 17-20]. 
 
 
i. Mode of action of GLP1R – mediated antidiabetic effects 
 
Figure 3 - Intracellular signaling 
pathways of GLP-1R in the pancreatic β-
cell. Adapated from Véronique Gigoux et 
al., 2013 [17] 
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Figure 4 - Pancreatic β-cell - stimulation 
of insulin secretion and biosynthesis. In 
Roman Vangoitsenhoven et al., 2012 
[15]. 
 
 
 
 
 
 
 
 
One of the main physiological roles of GLP-1 is to enhance insulin secretion in a glucose-
dependent manner. To stimulate insulin secretion and biosynthesis (Figure 3, green), GLP1 
binds to its specific GPCR, GLP-1R, activating downstream pathway of adenylate cyclase, 
which elevates intracellular cAMP levels leading to activation of Protein Kinase A (PKA) and 
cAMP-regulated guanine-nucleotide exchange factor II (cAMP-GEFII, also known as Epac2) 
signaling pathways. In the β-cell (Figure 4), GLP-1R activation accelerates glycolytic and 
mitochondrial metabolism of glucose, which is incorporated into the cell through GLUT-2, 
while also rendering K+-ATP channels more sensitive to the increase of ATP/ADP 
concentration ratio generated by the intracellular metabolism of glucose. In the presence of 
stimulatory levels of glucose and GLP-1, Ca2+ influx through the Ca2+ channels feeds forward 
into mobilization of Ca2+ from intracellular stores by Ca2+-induced Ca2+ release through PKA 
and cAMP-GEFII-dependent mechanisms. Ca2+ mobilization from intracellular stores will 
stimulate mitochondrial ATP synthesis, which will promote further membrane depolarization 
via closure of K+-ATP channels. ATP is also required for stimulation of exocytosis of the 
insulin-containing granules. The elevation in the cytoplasmic free Ca2+ concentration triggers 
the exocytotic response that is further potentiated by increased cAMP levels. This effect is 
mostly attributable to the ability of cAMP to accelerate granule mobilization resulting in an 
increased size of the pools of granules that are immediately available for release. These 
effects depend both on cAMP binding to PKA and cAMP-GEFII. These channels are 
sensitive to the intracellular ATP levels and, thereby, to glucose metabolism of the β-cells, 
but may also be affected (closed, resulting in subsequent depolarization of the plasma 
membrane and opening of voltage-sensitive Ca2+ channels) by PKA activated by GLP-1. In 
other words, GLP-1 increases glucose-induced membrane depolarization and therefore 
enhances insulin secretion in a glucose-dependent manner [1, 7, 14, 15, 17, 18, 20].  
GLP-1 plays also a key role in the homeostasis of β -cell mass by inducing β -cell 
proliferation (Figure 3, in blue) and protecting against apoptosis which favour an expansion 
of β -cell mass (Figure 3, in red). When GLP-1 binds to its receptor it induces homeobox-1 
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
ANDREIA FILIPA RODRIGUES DOS SANTOS Page 19  
gene activation, which promotes in the periductal pancreatic cells the differentiation towards 
β-cells, inhibiting the apoptosis. These functions are mediated via the activation of the 
cAMP/PKA/CREB (cAMP-responsive element binding protein) and the transactivation of the 
epidermal growth factor receptor (EGF-R) leading to the activation of phosphatidylinositol-3 
kinase (PI3K), Protein Kinase Cζ (PKCζ), Akt-protein kinase B, Extracellular Regulated 
Kinase (ERK1/2, also named Mitogen-Activated Protein Kinase [MAPK]) signaling pathways 
and to the up-regulation of the expression of the cell cycle regulator cyclin D1. The 
antiapoptotic effect of GLP-1 in β-cells also involves β-arrestin1 recruitment by GLP-1R 
which mediates the ERK1/2 activation leading to the phosphorylation and inactivation of the 
pro-apoptotic protein Bad [17].  
In addition to its stimulatory effect on insulin secretion, in the α-cell, GLP-1R activation 
inhibits glucagon secretion. In combination with enhanced insulin secretion, this decrease of 
glucagon leads to an improvement of glucose homeostasis, in particular in patients with 
T2DM [15, 17]. 
 
III. 2. Approved medicines of GLP-1R agonist class 
The GLP-1R agonists mimic the GLP-1 function in order to enhance insulin secretion after 
food-intake, restoring the incretin function, while are protected from the DPP-4 deactivation. 
This is achieved by binding to a GLP-1R that resides in the β-cell [1, 2, 15]. 
The first GLP-1R agonist to reach the market was exenatide, under the trade name BYETTA, 
which was approved in November 2006 in the EU and April 2005 in the U.S. It was 
discovered when it was noted that salivary protein from the Gila monster had properties 
similar to GLP-1. A synthetic version of this substance was produced and tested, and found 
to be effective. It has greater than 50% structural overlap with human GLP-1, binds to the 
human GLP-1R on the β-cell and is resistant to DPP-4 degradation [2].  
Following BYETTA several other medicinal products, belonging to GLP-1R agonists’ family, 
were approved. The following tables (Table 2 and Table 3) present the approved agonists of 
the GLP-1R in EU and U.S., respectively.  
Table 2 - GLP-1R agonists approved in EU  
Medicinal 
Product 
Active 
substance 
Authorisation 
date 
Marketing 
Authorisation 
Holder 
Strength 
Pharmaceutical 
Form 
BYETTA Exenatide 
November 
2006 
AstraZeneca 
AB 
5 
micrograms 
(mcg) 
10 mcg 
Solution for 
injection 
VICTOZA Liraglutide June 2009 
Novo Nordisk 
A/S 
6 mg/ml 
Solution for 
injection in pre-
filled pen 
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BYDUREON 
Exenatide 
extended-
release 
June 2011 
AstraZeneca 
AB 
2 mg 
Powder and 
solvent for 
prolonged 
release 
suspension for 
injection 
LYXUMIA  Lixisenatide February 2013 
Sanofi-Aventis 
Groupe 
10 mcg 
20 mcg 
10 mcg + 
20 mcg 
Solution for 
injection 
EPERZAN Albiglutide March 2014 
GlaxoSmithKli
ne Trading 
Services 
Limited 
30 mg 
50 mg 
Powder and 
solvent for 
solution for 
injection 
TRULICITY Dulaglutide 
November 
2014 
Eli Lilly 
Nederland 
B.V. 
0.75 mg 
1.5 mg 
Solution for 
injection 
 
 
Table 3 - GLP-1R agonists approved in U.S. 
Medicinal 
Product 
Active 
substance 
US 
authorisation 
date 
Marketing 
Authorisation 
Holder 
Strength 
Pharmaceutic
al Form 
BYETTA Exenatide 
April 2005 
 
October 2009 
AstraZeneca 
AB 
 
AMYLIN 
250 mcg/ ml 
Solution for 
injection 
VICTOZA Liraglutide January 2010 
Novo Nordisk 
Inc 
6 mg/ml 
Solution for 
injection in 
pre-filled pen 
BYDUREON 
Exenatide 
extended-
release 
January 2012 
AstraZeneca 
AB 
2 mg 
Powder and 
solvent for 
prolonged 
release 
suspension for 
injection 
ADLYXIN Lixisenatide July 2016 
Sanofi-Aventis 
US 
0.05 mg/ml 
0.1 mg/ml 
Solution for 
injection 
TANZEUM Albiglutide April 2014 
GlaxoSmithKli
ne LLC 
30 mg 
Powder and 
solvent for 
solution for 
injection 
TRULICITY  Dulaglutide September 2014 Eli Lilly and Co 
0.75 mg/ 0.5 
ml 
1.5 mg/ 0.5 
ml 
Solution for 
injection 
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These medicinal products have slight different therapeutic indications, as stated in the 
following table (Table 4).  
Table 4 - Approved therapeutic indications 
MEDICINAL PRODUCT THERAPEUTIC INDICATIONS 
BYETTA 
For treatment of T2DM in combination with: 
 metformin,  
 sulphonylureas (SUs),  
 thiazolidinediones (TZDs),  
 metformin and a SU,  
 metformin and a TZD  
in adults who have not achieved adequate glycaemic control on maximally 
tolerated doses of these oral therapies.  
 
As adjunctive therapy to basal insulin with or without metformin and/or 
pioglitazone in adults who have not achieved adequate glycaemic control 
with these agents [21, 22]. 
BYUDUREON 
For treatment of T2DM in combination with: 
 metformin,  
 SUs,  
 TZDs,  
 metformin and a SU,  
 metformin and a TZD 
in adults who have not achieved adequate glycaemic control on maximally 
tolerated doses of these oral therapies [23]. 
VICTOZA 
Treatment of adults with T2DM to achieve glycaemic control: 
 monotherapy, when diet and exercise alone do not provide 
adequate glycaemic control in patients for whom use of metformin is 
considered inappropriate due to intolerance or contraindications; 
and as combination therapy,  
 combination with oral glucose-lowering medicinal products and/or 
basal insulin when these, together with diet and exercise, do not 
provide adequate glycaemic control [24]. 
LYXUMIA/ADLYXIN 
Treatment of adults with T2DM to achieve glycaemic control in combination: 
 with oral glucose-lowering medicinal products 
 and/or basal insulin 
when these, together with diet and exercise, do not provide adequate 
glycaemic control [25-27]. 
EPERZAN/TANZEUM 
Treatment of T2DM in adults to improve glycaemic control: 
 monotherapy, when diet and exercise alone do not provide 
adequate glycaemic control in patients for whom use metformin is 
considered inappropriate due to contraindications or intolerance;  
 add-on combination therapy, in combination with other glucose-
lowering medicinal products including basal insulin, when these, 
together with diet and exercise, do not provide adequate glycaemic 
control. [28, 29] 
TRULICITY 
In adults with T2DM to improve glycaemic control: 
 monotherapy, when diet and exercise alone do not provide 
adequate glycaemic control in patients for whom the use of 
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metformin is considered inappropriate due to intolerance or 
contraindications;  
 add-on therapy, in combination with other glucose-lowering 
medicinal products including insulin, when these, together with diet 
and exercise, do not provide adequate glycaemic control [30, 31].  
 
The present work will focus on the GLP-1R agonists therapeutic class which includes five 
active substances and six different medicinal products approved both in the EU and in the 
U.S. (please refer to the tables above for further details). 
Lixisenatide and albiglutide have different trade names in the EU and in the U.S.. Therefore, 
whenever these active substances are analysed, both trade names will be referred. 
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THESIS OBJECTIVES  
Despite GLP-1R agonists are authorised in Europe since 2006 (BYETTA’s approval year), in 
Portugal only in 2014 the first GLP-1R agonists were reimbursed. The reimbursement was 
approved for VICTOZA in January 2014 and for BYDUREON in October 2014. BYETTA’s 
reimbursement request was rejected not showing therapeutic nor economic advantage. In 
coming years, it is expected that several other GLP-1R agonists become reimbursed.  
Reimbursement will allow much more patients to have access to these medicines, which in 
turn will increase the data not only on these medicinal products’ benefits but also on their 
adverse effects profile.  
The post-marketing experience gathered by other countries, both in the Europe and in the 
U.S., is of most importance, as it enables to draw a more accurate safety profile for these 
medicines and it allows deducing which will be the most serious adverse reactions to be 
expected in Portuguese patients.  
Therefore, the main goals of the present work are drawing a safety profile for GLP-1R 
agonists and conclude on the need and/or opportunity of adapting their RMPs for the new 
markets, taking into account the safety data collected both in the EU and in the U.S..  
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METHODOLOGY 
I. Research sources  
EMA and FDA were contacted by email, in order to obtain more and the most recent safety 
data regarding the medicinal products herein evaluated. EMA provided the RMPs for the 
concerned medicines and they indicated that the European Public Assessment Reports 
(EPARs) are available in the EMA’s website. Regarding FDA, they communicated that all 
data available are published in their website. 
Therefore, the data collected, reviewed, analysed, compared and summarised has been 
obtained mainly through online research in the following sources:  
Table 5 - Data sources used 
Data sources Analysed information 
Pubmed website [32] 
The New England Journal of Medicine website 
[33] 
Books, magazines, reports and presentations 
Articles, reviews and data on: 
- Diabetes epidemiology and physiopathology 
- Mechanism of action of the GLP-1R agonists 
- Safety profile of GLP-1R agonists 
EMA’s website [34] 
- EPARs 
- Summaries of the Product Characteristics 
(SmPCs) 
- Current approved antidiabetic therapies 
FDA’s website [35] 
- Risk Evaluation and Mitigation Strategy (REMS) 
- Medical review 
- Summary review 
- Risk assessment and risk mitigation review(s) 
- Approved information 
European database of suspected adverse drug 
reaction reports website [36] (database created 
in 2012) 
Suspected adverse drug reactions, occurred in the 
EU and non-EU, reported to EudraVigilance. 
DrugCite.com website [37] 
Adverse Events (AEs) reported through the FDA 
Adverse Events Reporting System (FAERS), up to 
the third quarter of 2012 
Risk Management Plans (RMPs) [9, 11, 38-41] 
- Safety concerns identified to each medicinal 
product 
- Routine and additional pharmacovigilance 
activities implemented 
 
For AEs listing, Medical Dictionary for Regulatory Activities (MedDRA 19.0) was used.  
 
II. Data treatment 
In a first step, a comparison in a table format between EPARs (nonclinical and clinical data) 
and RMPs is presented for each medicinal product. Following this, it is presented a resume 
table identifying the risks considered by EMA and those ones accepted by FDA. 
Since BYETTA and BYDUREON contain the same active substance, only the 
pharmaceutical form is different, it seems important to assess them in a stricter manner 
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allowing to understand if the extended-release formulation has a relevant role in the 
expression of any adverse reaction.  
 
In a second step, a comparison of adverse reactions reported both in the EU and in the U.S., 
if possible, within each medicinal product is presented. The methodology hereinafter 
described is similar to the one used by Francisca Lemos in her master thesis [42]. The data 
collected and compared was made available through different databases, with different data 
sources formats and classifications (Table 6).  
Table 6 - Differences in presentation of data pertaining to Adverse Drug Reactions (ADRs) reported in the EU and in the 
U.S. 
Data 
characteristics 
EU database of suspected adverse 
drug reaction reports [36] 
DrugCite.com website [37] 
Source 
EudraVigilance 
- Comprises reports from national 
competent authorities and 
pharmaceutical companies that hold 
marketing authorisations for the 
medicines. 
FAERS 
- Includes AEs if the drug is flagged as 
a suspect drug causing the AE.  
Updating 
frequency 
Cases reported up to the end of the 
previous month (updates are done on 
the 15th of the month) 
Uncertain (information not available) 
- At the time of data collection, only 
had data from Q1 2004 until Q3 2012 
Data format Chart format Chart format 
Charts data 
labels available 
Only displayed in the online format (for 
the purpose of this project, those were 
retrieved one by one) 
Yes 
Charts data 
classifications 
Number of individual cases by 
reaction groups – MedDRA System 
Organ Class (SOC) 
 
The reaction groups are based on a 
classification of the side effect (also 
known as adverse drug reaction), using 
the MedDRA dictionary of terms 
Top categories of AEs – MedDRA 
High-Level Group Terms (HLGT) 
 
Since the data retrieved from both the EU and the U.S. databases was significantly different, 
some treatment of data was necessary for enabling the comparison of the EU and the U.S. 
data.  
For each GLP-1R agonist, it was firstly analysed the EU and U.S. raw data and only then, a 
cumulative data chart was created. For that cumulative data chart to be created, some 
treatment of data was performed:  
- U.S. data classification was re-arranged and grouped into a classification similar to 
EU data classification: MedDRA SOC 
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- Only MedDRA SOC totals were displayed in the cumulative chart. Comparative 
charts, whenever possible, will be presented containing the EU and the U.S. data 
side-by-side. 
Regarding the ADRs data, all SOCs were assessed and only the relevant ones for the 
present work have been analysed. The most prevalent ADR terms were grouped into 
their respective PT term. The obtained results from both databases of the EU and the 
U.S., whenever possible, are presented in chart. 
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RESULTS  
BYETTA  
BYETTA 5 mcg solution for injection is a parenteral drug product for subcutaneous (SC) 
administration, twice a day (BID). It contains exenatide as active substance, which is an 
incretin mimetic. Exenatide was originally isolated from the salivary secretions of Heloderma 
suspectum (Gila monster), in which it circulates after meal initiation and may have endocrine 
functions [43].  
Exenatide is a chemically synthesized 39-amino-acid peptide. The synthesis using protected 
L-amino acids has been stereochemically controlled [43]. 
The amino acid sequence of exenatide partially overlaps (53%) that of human GLP-1. 
Exenatide has been shown to bind to and activate the known human GLP-1R in vitro [22, 
38].  
These medicinal product is approved in several therapeutic combinations, as identified in 
Table 4 - Approved therapeutic indications. 
Regarding the BYETTA’ safety profile, comparative analyses are presented. A comparison 
between safety information included in EPAR (nonclinical and clinical data) and in RMP is 
presented in Table 7. Table 8 resumes the safety concerns considered by EMA and those 
ones accepted by FDA.  
 
Table 7 - Comparative analysis on BYETTA’ safety profile 
 Nonclinical data [43] Clinical data [43] RMP data[38] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Rat:  
- Acute administration did not affect 
thyroid hormones T3 and T4 
- Reduction of plasma levels of 
thyroid stimulating hormone  
- Increased incidence of benign 
thyroid C-cell adenomas (highest 
dose - 130 times human 
exposure) 
 
Carcinogenicity 
Rat: 
- Increased incidence of benign 
thyroid C-cell adenomas (female; 
highest dose) 
- No increased incidence in C-cell 
carcinomas 
 
Reproduction Toxicity 
Mice / Rabbit: 
- Maternal food consumption and 
body weight reduced 
- Foetal growth slowed and skeletal 
variations – changes in rib pairs or 
vertebral ossification sites and 
wavy ribs 
- Maternal toxicity. 
Potential risks 
- Anti-exenatide antibodies; 
- Cardiovascular (CV) Events; 
- Risks of Elevated Pulse 
Rate; 
- Malignant Neoplasms; 
- Dehydration and Acute 
Renal Impairment; 
- Pancreatitis; 
- Increased International 
Normalisation Ratio (INR) 
with concomitant warfarin. 
 
Information to be completed 
- Adolescents; 
- Pregnant women; 
- Very elderly (>= 75 years of 
age). 
Identified risks 
At this time, no risks have been 
identified that would require 
further systematic study. 
 
Potential risks 
- Anti-exenatide Antibodies 
- CV Events 
- Malignant Neoplasms  
- Dehydration and acute renal 
impairment 
- Pancreatitis 
- Increased INR with 
concomitant Warfarin 
 
Missing information 
- Adolescents 
- Pregnant women 
- Very elderly (>= 75 years of 
age) 
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Table 8 - Summary of safety concerns considered by EMA and FDA 
 EMA [38, 43] FDA [44] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Identified risks 
No risks have been identified that would require 
further systematic study. 
 
Potential risks 
- Anti-exenatide Antibodies 
- CV Events 
- Malignant Neoplasms  
- Dehydration and acute renal impairment 
- Pancreatitis 
- Increased INR with concomitant Warfarin 
 
Missing information 
- Adolescents 
- Pregnant women 
- Very elderly (>= 75 years of age) 
- GI side effects: nausea, vomiting, diarrhoea and 
dyspepsia 
- Decrease the absorption of concomitant oral 
drugs 
- Hypoglycaemia, when used together with a SU 
- Anti-exenatide antibodies/ Immunogenicity 
- Use during pregnancy 
 
The safety concerns identified throughout the investigational cycle were presented in the 
aforementioned tables. Nevertheless, it is well-known that the results acquired during the 
clinical trials are scarce, when comparing to the “real world” data. Therefore, the post-
marketing data, i.e. the ADRs reported in the EU and in the U.S., are presented in individual 
charts. Additionally, a comparison of adverse reactions reported both in the EU and in the 
U.S., grouped by SOC, can be seen in a single chart.  
 
- European database of suspected adverse drug reaction reports  
The data herein presented was retrieved from European database adrreports.eu [36]. This 
website gives access to web reports on suspected ADRs by medicine or by active substance 
name. All the data displayed in the web reports is taken from EudraVigilance, a system 
designed for collecting reports of ADRs occurred within and outside the European Economic 
Area (EEA) [36]. This includes reports received from healthcare professionals and patients, 
reported by national competent authorities and Marketing Authorisation Holders (MAHs). 
The following charts (Chart 1 and Chart 2) illustrate the number of the ADRs reported up to 
July 2016 to EudraVigilance, grouped by SOC and by PT, respectively.  
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Chart 1 - Number of Individual Cases by Reaction Groups sorted by Geographic Origin in the EU for BYETTA 
 
 
Chart 2 - Adverse Events reported in the EU for BYETTA grouped by PT 
 
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
Page 30 ANDREIA FILIPA RODRIGUES DOS SANTOS 
- FDA Adverse Events Reporting System (FAERS) Data 
(DrugCite.com) 
The data herein presented was made available by DrugCite database [37]. The results 
included reports submitted by physicians, healthcare consumers, lawyers amongst others, 
previously assessed by FDA scientific staff.  
The following charts (Chart 3 and Chart 4) illustrate the number of the ADRs reported up to 
the Q3 2012 to FDA, grouped by SOC and by PT, respectively. 
 
 
Chart 3 - Number of Individual Cases by Reaction Groups in the U.S. for BYETTA 
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Chart 4 - Adverse Events reported in the U.S. for BYETTA grouped by PT 
 
- Comparison of adverse events reported in EU and U.S., 
grouped by SOC 
Herein it is included a cumulative chart regarding the ADRs reported for BYETTA both in the 
EU and in the U.S. grouped by SOC. This comparison allows a visually enhanced perception 
of differences between the EU (blue) and the U.S. (yellow) data.  
 
Chart 5 - Adverse Events reported in the EU and in the U.S. for BYETTA grouped by SOC 
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Following the analysis of the charts and tables previously presented, it became clear that 
there were some similarities and some discrepancies between the EU and the U.S. data: 
Main similarities: 
- GI disorder SOC is the most and the 2nd most prevalent in the EU and in U.S., 
respectively. Therefore, GI events, such as nausea, vomiting and diarrhoea, are among 
the ones most reported in both geographical areas.  
- Pancreatitis belong to the most reported ADRs.  
- Cardiac disorders SOC is amongst the less prevalent. 
- Weight decreased is the second most reported ADR.  
- Blood glucose increased belongs to the top 5 of the most reported ADRs, having the 
first place in the U.S.. 
- Anti-exenatide antibodies/immunogenicity (such as anaphylactic reactions), were 
identified as a risk in the EU an in the U.S.. Nevertheless, they were not reflected in the 
post-marketing reports, not being frequently reported.  
Main discrepancies:  
- GI AEs and hypoglycaemia were identified as a risk in the U.S. but not in the EU. 
- Pancreatitis, cardiovascular events and renal impairment were considered potential 
risks in the EU but not in the U.S.  
- Renal conditions and hypoglycaemia remain amongst the 35 most reported ADRs in 
the EU but not in the U.S.. 
- Malignant neoplasms were, during the pre-marketing phase, considered potential risks 
in the EU but not in the U.S.. Accordingly, the Neoplasms benign, malignant and 
unspecified SOC is the third most reported in EU, but in the U.S. this SOC is comprised 
under the ones less reported.  
- Nervous system disorders is the 3rd most prevalent SOC in the U.S., but not in the EU.  
- The visual perception enabled by Chart 5 lead to hypothesised that in the U.S. the 
reporting rate is much higher than in the EU. Therefore, the real proportion of results is 
not comparable. However, if a dispersion curve is imagined, it is possible to realize that 
the trend could be similar when the same number of U.S. reports will be achieved in 
the EU.  
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BYDUREON 
BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection is a 
parenteral drug product for weekly (QW) and SC administration of the known active 
substance exenatide. Exenatide QW consists of exenatide (5%) and sucrose (2%) 
encapsulated within biodegradable poly(D,L-lactide-co-glycolide) (PLG) microspheres that 
are designed to release exenatide over an extended period of time [45].  
BYDUREON thereby represents the first long acting GLP-1 analogue submitted for 
marketing authorisation. In Exenatide QW, exenatide will remain in plasma at levels above 
lower limit of quantification (LLOQ) (10 pg/ml) for 10 weeks after treatment interruption [45]. 
In comparison with Exenatide BID, overall systemic exposure is higher following treatment 
with BYDUREON and the washout period is longer, which can have potential implications for 
clinical safety [45].  
This medicinal product is approved in several therapeutic combinations, as identified in Table 
4 - Approved therapeutic indications. 
The primary pharmacologic, pharmacokinetic, and toxicological properties of the exenatide 
peptide were well characterised during the development of Exenatide BID. Therefore, most 
of the nonclinical pharmacology information presented for BYDUREON stems directly from 
the nonclinical program for Exenatide BID. The primary aim of the nonclinical studies 
conducted specifically for exenatide QW focused on determining the impact of the extended-
release formulation on the pharmacologic, pharmacokinetic, and toxicological profile of 
exenatide. In addition, these studies assessed the local tolerance (i.e. injection site reaction) 
of the exenatide QW formulation and also monitored for the emergence of anti-exenatide 
antibodies [45, 46]. 
Studies with exenatide QW were performed to compare pharmacokinetic profiles between 
the two formulations. After a SC injection of exenatide QW, absorption occurs over an 
extended period of time, i.e. weeks in monkeys and rats [45].  
The following tables (Table 9 and Table 10) encompass the comparative analyses regarding 
the safety profile of BYDUREON, either between information included in EPAR and in RMP 
as well as between the safety concerns accepted by EMA and by FDA.  
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Table 9 - Comparative analysis on BYDUREON' safety profile 
 Nonclinical data [45] Clinical data [45] RMP data [9] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Toxicokinetics 
Rat/monkey: 
- Injection site reactions 
- Anti-exenatide antibodies 
 
Carcinogenicity 
Mice: 
- No increase in neoplastic lesions 
Rat: 
- Thyroid tumours (both sexes) – not of 
C-cell origin 
- Parathyroid gland adenoma (mid- and 
high-dose males) 
 
Reproduction/ Developmental 
Toxicity 
Rat: 
- Maternal and foetal toxicity 
(decreased food intake and body 
weight decrease; growth retardation/ 
developmental delay, respectively) 
 
Local tolerance 
- Injection site reactions 
 
Antigenicity/ Immunogenicity 
- Exenatide QW more immunogenic 
than for exenatide BID. 
Rat/ Monkey: 
- Antibodies observed  
Safety concerns 
- Pancreatitis 
- Acute Renal Failure 
- Rapid Weight Loss 
- Risks associated with Anti-
exenatide antibodies: focus 
on anaphylactic-type 
reactions – immunological 
events 
- Injection site related-events; 
hypersensitivity 
- Cardiac Events 
- Malignant Neoplasms: focus 
on pancreatic cancer and 
thyroid neoplasms 
- Adolescents – assess safety 
and efficacy  
- Pregnant Women – 
pregnancy registry 
- Very Elderly (≥ 75 years of 
age) 
- Use of exenatide in 
combination with TZDs 
- Severe GI Disease 
- Various Degrees of Impaired 
Renal  
- Hepatic Impairment 
Important identified risks 
- Pancreatitis  
- Acute Renal failure  
- Rapid Weight Loss 
 
Important Potential Risks 
- Risk(s) associated with Anti-
Exenatide Antibodies: focus 
on anaphylactic-type 
reactions  
- Cardiac events  
- Malignant Neoplasms: 
Focus on Pancreatic Cancer 
and Thyroid Neoplasms 
 
Missing information 
- Adolescents 
- Pregnant women 
- Very elderly (≥ 75 years old) 
- Potential for Concomitant 
use with TZDs 
- Severe GI disease 
- Various degrees of impaired 
renal function 
- Hepatic impairment 
 
Table 10 - Summary of safety concerns considered by EMA and FDA for BYDUREON 
 EMA FDA [46] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Important Identified Risks 
- Pancreatitis  
- Acute Renal failure  
- Rapid Weight Loss 
 
Important Potential Risks 
- Risk(s) associated with Anti-Exenatide Antibodies: 
focus on anaphylactic-type reactions  
- Cardiac events  
- Malignant Neoplasms: Focus on Pancreatic Cancer 
and Thyroid Neoplasms 
 
Missing Information 
- Adolescents 
- Pregnant women 
- Very elderly (≥ 75 years old) 
- Potential for Concomitant use with TZDs 
- Severe GI disease 
- Various degrees of impaired renal function 
- Hepatic impairment 
- GI AEs (less frequently with BYDUREON 
than with BYETTA) 
- Renal impairment 
- Pancreatitis 
- Thyroid tumours: increased risk  
- Injection site nodules and reactions 
- CV: small increase in heart rate 
- Hypersensitivity/ immunogenicity (anti-
exenatide antibodies) 
- Hypoglycaemia (in combination with SU) 
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All identified and potential risks discussed were initially identified in the clinical development 
program for exenatide BID or through post-marketing experience with Exenatide twice daily 
[45].  
Despite BYETTA and BYDUREON contain the same active substance, the pharmaceutical 
form is different and it seems important to assess them distinctly. Therefore, the ADRs 
reported in the EU and in the U.S., are presented in individual charts. Additionally, a 
comparison of ADRs reported both in the EU and in the U.S., grouped by SOC, can be seen 
in a single chart.  
 
- European database of suspected adverse drug reaction reports  
The data herein presented was retrieved from European database adrreports.eu [36]. This 
website gives access to web reports on suspected ADRs by medicine or by active substance 
name. All the data displayed in the web reports is taken from EudraVigilance, a system 
designed for collecting reports of ADRs occurred within and outside the EEA [36]. This 
includes reports received from healthcare professionals and patients, reported by national 
competent authorities and MAHs. 
The following charts (Chart 6 and Chart 7) illustrate the number of the ADRs reported up to 
July 2016 to EudraVigilance, grouped by SOC and by PT, respectively.  
 
 
Chart 6 - Number of Individual Cases by Reaction Groups sorted by Geographic Origin in the EU for BYDUREON 
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Chart 7 - Adverse Events reported in the EU for BYDUREON grouped by PT 
 
- FDA Adverse Events Reporting System (FAERS) Data 
(DrugCite.com) 
The data herein presented was made available by DrugCite database [37]. The results 
included reports submitted by physicians, healthcare consumers, lawyers amongst others, 
previously assessed by FDA scientific staff.  
The following charts (Chart 8 and Chart 9) illustrate the number of the ADRs reported up to 
the Q3 2012 to FDA, grouped by SOC and by PT, respectively. 
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Chart 8 - Number of Individual Cases by Reaction Groups in the U.S. for BYDUREON 
 
 
Chart 9 - Adverse Events reported in the U.S. for BYDUREON grouped by PT 
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- Comparison of adverse events reported in EU and U.S., 
grouped by SOC 
Herein it is included a comparison chart regarding the ADRs reported for BYDUREON both 
in the EU and in the U.S. grouped by SOC. 
 
 
Chart 10 - Adverse Events reported in the EU and in the U.S. for BYDUREON grouped by SOC 
 
Following the analysis of the charts and tables previously presented, it became clear that 
there were some similarities and some discrepancies between the EU and the U.S. data: 
Main similarities:  
- Pancreatitis, CV events and renal disorder were identified as risks in both the EU and 
the U.S.. 
- GI disorder and General disorders and administration site conditions SOCs are the two 
most prevalent in the EU and in the U.S.. Therefore, GI events, such as nausea, 
vomiting and diarrhoea, as well as administration site reactions are among the ones 
most reported in both geographical areas.  
- Nervous system disorders SOC appears among the most prevalent SOCs, being the 
4th most reported in the EU and in the U.S..  
- Weight decreased remains in the podium of the most reported events, being the 2nd 
most reported ADR in the U.S. and the 3rd in the EU.  
- Blood glucose increased belongs to the top 5 of the most reported ADRs, having the 1st 
place in the U.S.. 
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- Regarding anti-exenatide antibodies/immunogenicity, it was identified as a risk in the 
EU an in the U.S.. Nevertheless, it was not reflected in the post-marketing reports as 
not being frequently reported. 
 
Main discrepancies:  
- Despite the scarcity of data in the U.S., the visual perception allowed by Chart 10 
shows that the dispersion of the results trend to be the same, since the most prevalent 
SOCs are, in a general manner, similar in both sides of the chart.  
- GI AEs were identified as risk in the U.S. and severe GI disease was classified as 
missing information in the EU.  
- Hypoglycaemia was identified as a risk in the U.S. but not in the EU. However, in the 
EU it belongs to the first 35 ADRs reported, not happening the same in the U.S..  
- Malignant neoplasms, such as pancreatic cancer and thyroid neoplasms are potential 
risks in the EU, whereas in the U.S. only the occurrence of an increasing in thyroid 
tumours are potentially linked with BYDUREON. The prevalence of Neoplasms benign, 
malignant and unspecified SOC is much higher in the EU than in the U.S..  
- Pancreatitis belong to the most reported ADRs in the EU not in the U.S.. 
- In the U.S. Cardiac disorders is amongst the most prevalent SOC, being the 6th most 
reported, whereas in the EU it ranks the 11th place.  
- In the U.S. injection site nodules and reactions have been identified as risks associated 
with the use of BYDUREON, whilst in the EU these were not stated as identified or 
potential risks for this medicinal product.  
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BYETTA VS BYDUREON 
The integrated clinical trial data for exenatide once weekly was carefully examined to identify 
unique risks associated with the sustained-release formulation. No new risks were identified 
from the integrated once-weekly clinical trial database, and the identified and potential risks 
from the existing formulation did not exhibit an unique pattern of occurrence or severity with 
sustained-release formulation [45]. 
The short-term safety profile of exenatide QW seem to be largely similar to the BID 
formulation. However, potential long term effects of the QW dosing are more difficult to 
evaluate considering the differences in pharmacokinetic profile between the once weekly and 
the twice daily formulation of exenatide [45].  
The marketing authorisation applicant submitted a RMP including both exenatide BID 
(BYETTA) and exenatide QW (BYDUREON) [45]. Therefore, the table presented below 
(Table 11) resumes the safety concerns considered for both medicinal products, according to 
the concerned RMP.  
 
Table 11 - Comparative analysis - BYETTA vs BYDUREON 
 BYETTA*[9] BYDUREON [9] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Important Identified risks 
- Pancreatitis 
- Acute Renal failure 
- Rapid Weight Loss 
 
Important Potential risks 
- Risk(s) associated with Anti-Exenatide 
Antibodies: anaphylactic-type reactions and 
hypersensitivity 
- Cardiac events  
- Malignant Neoplasms: Focus on Pancreatic 
Cancer and Thyroid Neoplasms. 
 
Missing information 
- Adolescents 
- Pregnant women 
- Very elderly (≥ 75 years old) 
- Potential for Concomitant use with TZDs 
Important identified risks 
- Pancreatitis  
- Acute Renal failure  
- Rapid Weight Loss 
 
Important Potential Risks 
- Risk(s) associated with Anti-Exenatide Antibodies: 
anaphylactic-type reactions and hypersensitivity 
- Cardiac events  
- Malignant Neoplasms: Focus on Pancreatic Cancer 
and Thyroid Neoplasms. 
Missing information 
- Adolescents 
- Pregnant women 
- Very elderly (≥ 75 years old) 
- Potential for Concomitant use with TZDs 
- Severe GI disease 
- Various degrees of impaired renal function 
- Hepatic impairment. 
* In the RMP submitted for BYDUREON, the safety concerns of exenatide BID were updated [9]. 
It seems important to assess BYETTA and BYDUREON in a stricter manner in order to 
understand if the extended-release formulation has a relevant role in the expression of any 
adverse reaction. Therefore, the ADRs reported in the EU are presented in three 
comparative charts, Chart 11, Chart 12 and Chart 13. The EU data were chosen as in the 
U.S. the data presented reported only up to the Q3 2012.  
- Comparison regarding SOC 
Below is presented a single chart comparing the total number of ADRs reported within 
each SOC for BYETTA and for BYDUREON, up to July 2016.  
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Chart 11 - Adverse Events reported in the EU for BYETTA and BYDUREON grouped by SOC 
 
- Comparison regarding PT terms 
 
 
Chart 12 - Adverse Events reported in the EU for BYETTA and BYDUREON grouped by PT. The most prevalent PTs for 
BYETTA and the respective values for BYDUREON 
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Chart 13 - Adverse Events reported in the EU for BYETTA and BYDUREON grouped by PT. The most prevalent PTs for 
BYDUREON and the respective values for BYETTA 
 
Following the analysis of the charts and tables previously presented, it became clear that 
there were some similarities and some discrepancies between BYETTA and BYDUREON 
safety profile: 
Main similarities:  
- As previously stated, the BYETTA’ safety concerns were updated in the BYDUREON’s 
RMP, since the new data acquired for BYDUREON indicated similarities in the safety 
concerns to both pharmaceutical formulations. The important and potential risks are the 
same for both medicinal products.  
- GI disorder SOC is the most prevalent SOC for both medicinal products. The GI 
events, such as nausea, vomiting and diarrhoea are among the mostly reported.  
- Pancreatitis is an important identified risk. In spite of having much more reports in 
BYETTA than in BYDUREON, pancreatitis is the most reported ADR with BYETTA and 
the 2nd most reported with BYDUREON.  
- Cardiac events are considered potential risks. Cardiac disorders SOC have the same 
prominence with both medicines, being in the 11th place for BYETTA and BYDUREON.  
- Weight decreased remains in the podium of the most reported events, being the 2nd 
mostly reported ADR with BYETTA and the 3rd with BYDUREON.  
- Blood glucose increased occupies the 5th position of the most reported ADRs for both 
medicinal products. 
- Anti-exenatide antibodies/immunogenicity was identified as a potential risk with both 
medicines. Nevertheless, it was not reflected in the post-marketing reports, as not 
being frequently reported. 
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Main discrepancies:  
- As previously stated, the BYETTA’ safety concerns were updated in the BYDUREON’s 
RMP. The differences remain at the missing information level, as severe GI disease, 
various degrees of renal function impairment and hepatic impairment were considered 
for BYDUREON. Regarding the Hepatobiliary disorders SOC, its prominence is much 
higher with BYETTA (10th position) than with BYDUREON (17th position).  
- General disorders and administration site conditions SOC is the 2nd most prevalent with 
BYDUREON but not with BYETTA. In accordance with this, administration site 
reactions are the mostly reported with BYDUREON and they are among the less 
reported with BYETTA.  
- Acute renal failure is an important identified risk for both medicines. Nevertheless, it is 
possible to see that the SOC Renal and urinary disorders has more prevalence with 
BYETTA than with BYDUREON, having the 7th and the 11th places respectively.  
- Malignant neoplasms, with focus on pancreatic cancer and thyroid neoplasms, are 
important identified risks for both medicinal product. However, and in line with what is 
seen for renal disorders, the prevalence of the Neoplasms benign, malignant and 
unspecified SOC is much higher with BYETTA (3rd place in prevalence) than with 
BYDUREON (9th place). Accordingly, pancreatic carcinoma is the 3rd ADR with more 
reports in BYETTA, and if pancreatic carcinoma metastatic is added it moves to the 2nd 
position. Additionally, thyroid cancer belongs to the top 35 of the most reported ADRs 
for BYETTA. For BYDUREON these reactions are not among the mostly reported as 
occurs to BYETTA.  
- BYETTA had a marketing authorisation granted in 2006 in the EU while BYDUREON 
only had marketing authorisation granted five years later, in 2011. Thus, BYETTA has 
much more post-marketing data than BYDUREON, which may bias the analysis. 
Nonetheless, the visual perception enabled by Chart 11 lead to hypothesised that if a 
dispersion curve is imagined the trend could be similar if the same number of BYETTA 
reports would be achieved by BYDUREON, with the exception of General disorders 
and administration site conditions and Renal and urinary disorders SOC.  
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VICTOZA 
VICTOZA is a 6 mg/ml solution for injection in a pre-filled pen once a day. Its active 
substance is liraglutide. Liraglutide is a long-acting analogue of the naturally occurring 
human GLP-1 with 97% homology and a lipophilic substituent for prolongation of half-life. 
This analogue is produced using the recombinant DNA technology in Yeast (Saccharomyces 
cerevisiae). Unlike GLP-1, liraglutide has a pharmacokinetic and pharmacodynamics profile 
in human suitable for once daily administration. Thus, liraglutide is administered once daily 
subcutaneously for the convenience of the patient and to improve compliance. Following SC 
administration, the protracted action profile is based on three mechanisms: self-association, 
which results in slow absorption, and binding to albumin and enzymatic stability towards the 
DPP-4 enzyme both resulting in a prolonged plasma half-life [47].  
These medicinal product is approved in monotherapy and in several therapeutic 
combinations, as identified in Table 4 - Approved therapeutic indications. 
Regarding the VICTOZA’ safety profile, comparative analyses are presented. A comparison 
between safety information included in EPAR (nonclinical and clinical data) and in RMP is 
presented in Table 12. Table 13 resumes the safety concerns considered by EMA and those 
ones accepted by FDA.  
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Table 12 - Comparative analysis on VICTOZA' safety profile 
 Nonclinical data [47] Clinical data [47] RMP data [39] 
S
a
fe
ty
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o
n
c
e
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s
 
Mice/ Rat/ Monkey: 
- Decreased body weight gain and food 
consumption  
 
Cardiotoxicity: 
Rat: 
- Increases in blood pressures and heart 
rate (dose-related) 
 
Carcinogenicity: 
Mice 
- C-cell tumours 
- Uterus leioma and leiosarcoma 
- Skin sarcomas increased (high dose) 
Rat: 
- C-cell tumours (longer studies) 
Monkey: 
- Increased pancreatic weight (increased 
duct cell mass and exocrine cells) 
- No C-cell hyperplasia and changes in 
C-cell mass 
 
Antigenicity/ Immunogenicity: 
Monkey: 
- Antibodies found (immunological 
reaction possible) 
 
Reproduction Toxicity 
Rat: 
- Decreased weight gain 
- crosses the placental barrier 
Rabbit: 
- Large decrease in food consumption 
(embryofoetal toxicity studies) 
- crosses the placental barrier 
Dog: 
- Secreted into dog breast milk 
- amount that a pup would receive per 
day via breast milk is low (at most 3% 
of the maternal dose) 
 
Local tolerance 
Pig: 
- Subacute inflammation in the injection 
site tissue 
Rat/ Monkey 
- Effects at the injection site (repeat dose 
toxicity studies) 
 
Immunotoxicity 
- No studies performed no relevant 
findings on the immune system organs 
observed in repeat dose studies.  
Identified safety issues 
-  Hypoglycaemia 
- GI AEs including nausea, 
diarrhoea, vomiting, 
constipation, dyspepsia 
 
Potential Safety Issues 
- Medullary Thyroid cancer 
- Neoplasm 
- Cardiac co-morbidity 
- Late stage microvascular 
complication of the eye 
- Immunogenicity (antibody 
formation, allergic reactions 
and injection site disorders) 
- Pancreatitis 
 
Missing information 
- Abuse due to weight 
lowering potential 
- Children and adolescents 
- Overdose 
- Pregnant and lactating 
women 
- Potential interaction with 
warfarin 
- Cardiac co-morbidity 
- Renal and hepatic 
impairment/endstage renal 
failure 
- Off-label use 
Important Identified risks 
- Hypoglycaemia 
- GI AEs: nausea, diarrhoea, 
vomiting, constipation and 
dyspepsia 
 
Important Potential risks 
- Medullary thyroid cancer 
(c-cell carcinogenicity) 
- Neoplasms 
- Pancreatitis 
- Immunogenicity – antibody 
development and allergic 
reactions 
- Injection site disorders 
- Cardiac co-morbidity 
- Late stage microvascular 
eye complication 
 
Missing information 
- Pregnant and lactating 
women 
- Children and adolescents 
<18 years 
- Overdose 
- Abuse due to weight 
lowering potential 
- Congestive heart failure 
NYHA I-IV 
- Drug-drug interaction with 
warfarin 
- Benefit-risk in patients with 
hepatic or renal 
impairment/end stage renal 
disease 
- Off-label use 
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Table 13 - Summary of safety concerns considered by EMA and FDA for VICTOZA 
 EMA FDA [46] [48] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Important Identified risks 
- Hypoglycaemia 
- GI AEs: nausea, diarrhoea, vomiting, constipation and 
dyspepsia 
 
Important Potential risks 
- Medullary thyroid cancer (c-cell carcinogenicity) 
- Neoplasms 
- Pancreatitis 
- Immunogenicity – antibody development and allergic 
reactions  
- Injection site disorders 
- Cardiac co-morbidity 
- Late stage microvascular eye complication 
 
Missing information 
- Pregnant and lactating women 
- Children and adolescents <18 years 
- Overdose 
- Abuse due to weight lowering potential 
- Congestive heart failure NYHA I-IV 
- Drug-drug interaction with warfarin 
- Benefit-risk in patients with hepatic or renal 
impairment/end stage renal disease 
- Off-label use 
- GI AEs, e.g. nausea, vomiting and 
diarrhoea. 
-  Anti-drug antibody formation – 
Hypersensitivity reactions 
- Injection site reactions 
- Hypoglycaemia  
- Medullary thyroid cancer  
- Pregnancy and lactation 
- Major adverse CV events - QT 
prolongation 
- Pancreatic issues: pancreatitis or 
pancreatic cancer 
- Dose-related carcinogenic potential 
 
- European database of suspected adverse drug reaction reports  
The data herein presented was retrieved from European database adrreports.eu [36]. This 
website gives access to web reports on suspected ADRs by medicine or by active substance 
name. All the data displayed in the web reports is taken from EudraVigilance, a system 
designed for collecting reports of ADRs occurred within and outside the EEA [36]. This 
includes reports received from healthcare professionals and patients, reported by national 
competent authorities and MAHs. 
The following charts (Chart 14 and Chart 15) illustrate the number of the ADRs reported up 
to July 2016 to EudraVigilance, grouped by SOC and by PT, respectively.  
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Chart 14 - Number of Individual Cases by Reaction Groups sorted by Geographic Origin in the EU for VICTOZA 
 
 
Chart 15 - Adverse Events reported in the EU for VICTOZA grouped by PT 
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- FDA Adverse Events Reporting System (FAERS) Data 
(DrugCite.com) 
The data herein presented was made available by DrugCite database [37]. The results 
included reports submitted by physicians, healthcare consumers, lawyers amongst others, 
previously assessed by FDA scientific staff.  
The following charts (Chart 16 and Chart 17) illustrate the number of the ADRs reported up 
to the Q3 2012 to FDA, grouped by SOC and by PT, respectively. 
 
 
Chart 16 - Number of Individual Cases by Reaction Groups in the U.S. for VICTOZA 
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Chart 17 - Adverse Events reported in the U.S. for VICTOZA grouped by PT 
 
- Comparison of adverse events reported in the EU and in the 
U.S., grouped by SOC 
Herein it is included a comparison chart regarding the ADRs reported for VICTOZA both in 
the EU and in the U.S. grouped by SOC. 
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Chart 18 - Adverse Events reported in the EU and in the U.S. for VICTOZA grouped by SOC 
 
Following the analysis of the charts and tables previously presented, it became clear that 
there were some similarities and some discrepancies between the EU and the U.S. data: 
Main similarities:  
- Hypoglycaemia is considered a risk both in the EU and in the U.S.. Hypoglycaemia and 
blood glucose decreased have been reported across the EU and in the U.S..  
- GI AEs, such as nausea, diarrhoea, vomiting, constipation and dyspepsia are important 
identified risks associated with VICTOZA. Accordingly, GI disorder SOC is the SOC 
with the major number of cases reported in the EU and in the U.S., and so these 
reactions are among the ones most reported.  
- Pancreatitis belong to the list of potential risks associated with the use of VICTOZA, 
both in the EU not in the U.S. This risk is corroborated by the real-world data, since 
represents the 1st ADR mostly reported in the EU and is also among the ADRs mostly 
reported in the U.S.  
- Weight decreased are not identified as risk to VICTOZA but it remains one of the most 
reported reactions, being the 5th mostly reported ADR in the U.S. and the 7th in the EU.  
- Blood glucose increased not considered as a risk, is the 2nd reaction mostly reported in 
the U.S. and the 10th in the EU.  
- Nervous system disorders SOC appears among the most prevalent SOCs both in the 
U.S. and in the EU.  
- Regarding immunogenicity and hypersensitivity reactions, they were identified as risks 
in the EU an in the U.S.. Nevertheless, they were not reflected in the post-marketing 
reports as not being frequently reported. 
- Injection site reactions were identified in the pre-marketing phase as being risks for this 
medicinal product in the EU and in the U.S.. 
- By the visual perception allowed by Chart 18 it is possible to conclude that the data 
dispersion trend to be similar in the EU and in the U.S.. In general, the SOC mostly 
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prevalent in the EU trend to be the same in the U.S., except for the SOC Neoplasms 
benign, malignant and unspecified which is the major discrepancy. 
Main discrepancies:  
- Malignant neoplasms, such as pancreatic cancer and thyroid neoplasms are potential 
risks in the EU and in the U.S., but the post-marketing prevalence is higher in the EU 
and not in the U.S.. The SOC Neoplasms benign, malignant and unspecified is the 2nd 
most prominent in the EU and belongs to the less reported in the U.S.. Moreover, 
concerning the PTs charts, pancreatic carcinoma is the 2nd most reported and thyroid 
carcinomas are also presented in the top 35 ADRs in the EU, while in the U.S. no 
carcinomas are presented in the top 35.  
- CV events were considered risks for this medicinal product in the both geographical 
areas. However, the prevalence in the EU is superior than the prevalence in the U.S., 
as the SOC Cardiac disorders is on the 9th position of prevalence whereas in the U.S. 
it is on the 12th position.  
- On the basis of the charts results, General disorders and administration site conditions 
SOC is the 3rd most reported in the U.S. and the 4th in the EU. Regarding the PTs, 
injection site reactions are often reported in the U.S. but they are not in the EU.  
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LYXUMIA / ADLYXIN 
LYXUMIA is an antidiabetic medicine that contains the active substance lixisenatide. It is 
available as a solution for injection in a pre-filled pen that provides either 10 mcg or 20 mcg 
of lixisenatide in each dose. It is subcutaneously administered once a day, within the hour 
prior to the first meal of the day or the evening meal. [27, 41] 
Lixisenatide is a GLP-1R agonist resistant to enzymatic cleavage by DPP-4. This results in a 
longer duration of action enabling the use lixisenatide for therapeutic purposes. The 
recommended maintenance dose is 20 mcg once daily; which is achieved after a 2-week 
starting regimen of lixisenatide 10 mcg once daily [25]. 
Lixisenatide is a synthetic peptide containing 44 amino acids, which is amidated at the C-
terminal amino acids. This active substance had a binding affinity approximately 4 times 
greater than native human GLP-1 to GLP-1R [25]. 
These medicinal product is approved in several therapeutic combinations, as identified in 
Table 4 - Approved therapeutic indications. 
Specific safety issues related to potential risks of medullary thyroid cancer, pancreatitis, 
malignant neoplasms, propensity to induce a transient increased heart rate, and 
malformations observed in animal development studies have been evaluated and are 
addressed in SmPC and /or RMP [49]. The following table (Table 14) encompasses the 
comparative analyses regarding the safety profile of LYXUMIA between information included 
in EPAR and in RMP. 
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Table 14 - Comparative analysis on LYXUMIA' safety profile 
 Nonclinical data [25] Clinical data [25] RMP data [39] 
S
a
fe
ty
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o
n
c
e
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s
 
Rat:  
- Testicular and epidydimal effects (high dose): 
atrophy, spermatid stasis and mineralisation in 
the testis and oligospermia and aspermia in 
the epididymis 
- Limited increase in mean arterial blood 
pressure. 
Dog: 
- Reversible testicular and epidydimal toxicities.  
 
Carcinogenicity: 
Rat:  
- Proliferative effects on thyroid C-cells 
Mice:  
- Proliferative effects on thyroid C-cells 
 
Reproduction Toxicity 
Rat:  
- Microphthalmia, anophthalmia, diaphragm 
hernia and multiple skeletal malformations 
- Retardation of foetal growth and ossification 
(dose-dependent) 
- Maternal toxicity: decreased motor activity, 
piloerection, decreased body weight and food 
consumption 
Rabbits: 
- Multiple malformations 
- Skeletal and visceral anomalies and retarded 
ossification 
 
Antigenicity/ Immunogenicity 
Mice/ rat/ dog: 
- Antidrug antibodies  pharmacokinetics with 
higher exposures 
Important identified risks  
- GI events i.e. nausea, 
vomiting  
- Systemic hypersensitivity 
reactions  
- Hypoglycaemia, when 
used with a SU or basal 
insulin 
 
Important potential risks  
- CV events  
- Acute pancreatitis  
- Medullary thyroid cancer  
- Malignant neoplasm  
-  Immunogenicity / 
Neutralization  
- Dehydration / Acute renal 
impairment  
- - Off-label use in non-
T2DM for weight loss  
- Teratogenicity  
 
Missing information  
- Use in pregnant women  
- Use in lactating women  
-  Use in children and 
adolescents <18 years  
-  Use in very elderly (≥75 
years)  
-  Use in patients with 
moderate and severe 
renal impairment (with 
and without low body 
weight) 
Important identified risks  
-  GI events i.e. nausea, 
vomiting  
-  Systemic hypersensitivity 
reactions  
-  Hypoglycaemia, when 
used with a SU or basal 
insulin 
 
Important potential risks  
-  CV events  
-  Acute pancreatitis  
-  Medullary thyroid cancer  
- Malignant neoplasm  
-  Immunogenicity / 
Neutralization  
-  Dehydration 
- Acute renal impairment  
- Off-label use in non-
T2DM for weight loss  
-  Teratogenicity  
 
Missing information  
-  Use in pregnant women  
- Use in lactating women  
-  Use in children and 
adolescents <18 years  
- Use in very elderly (≥75 
years)  
-  Use in patients with 
moderate and severe 
renal impairment (with 
and without low body 
weight) 
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Table 15 - Summary of safety concerns considered by EMA and FDA for LYXUMIA / ADLYXIN 
 EMA FDA [50] 
S
a
fe
ty
 c
o
n
c
e
rn
s
 
Important identified risks  
-  GI events i.e. nausea, vomiting  
-  Systemic hypersensitivity reactions  
-  Hypoglycaemia, when used with a SU or basal insulin 
 
Important potential risks  
-  CV events  
-  Acute pancreatitis  
-  Medullary thyroid cancer  
- Malignant neoplasm  
-  Immunogenicity / Neutralization  
-  Dehydration / Acute renal impairment  
- Off-label use in non-T2DM for weight loss  
-  Teratogenicity  
 
Missing information  
-  Use in pregnant women  
- Use in lactating women  
-  Use in children and adolescents <18 years  
- Use in very elderly (≥75 years)  
-  Use in patients with moderate and severe renal 
impairment (with and without low body weight) 
- GI events (i.e. mainly nausea and vomiting) 
- Hypoglycaemia increased when used with 
SU or insulin 
- Immunogenicity  
- Hypersensitivity 
- Pancreatitis 
- Renal impairment in patients with severe GI 
reactions 
- Medullary thyroid cancer 
- Other malignancies 
 
- European database of suspected adverse drug reaction reports  
The data herein presented was retrieved from European database adrreports.eu [36]. This 
website gives access to web reports on suspected ADRs by medicine or by active substance 
name. All the data displayed in the web reports is taken from EudraVigilance, a system 
designed for collecting reports of ADRs occurred within and outside the EEA [36]. This 
includes reports received from healthcare professionals and patients, reported by national 
competent authorities and MAHs. 
The following charts (Chart 19 and Chart 20) illustrate the number of the ADRs reported up 
to July 2016 to EudraVigilance, grouped by SOC and by PT, respectively.  
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Chart 19 - Number of Individual Cases by Reaction Groups sorted by Geographic Origin in EU for LYXUMIA 
 
 
Chart 20 - Adverse Events reported in EU for LYXUMIA grouped by PT 
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- FDA Adverse Events Reporting System (FAERS) Data 
(DrugCite.com) 
This database includes information regarding the number of the ADRs reported since the 
authorisation date up to the Q3 2012 to FDA. As ADLYXIN was only approved in 2016 in 
U.S., there is no data available.  
- Comparison of adverse events reported in EU and U.S., 
grouped by SOC 
As no data is available from FDA, it was not possible to perform this comparison.  
 
As aforementioned, it is no possible to perform a comparison between the post-marketing 
data in the EU and in the U.S., as no U.S. data are available. However, on the basis of the 
charts and tables previously presented, it is possible to perform the following analysis:  
- GI AEs, such as nausea and vomiting are important identified risks both in the EU and 
in the U.S.. Accordingly, in the EU, GI disorder SOC is the SOC with the major number 
of cases reported, and nausea and vomiting are the 1st and 2nd most reported ADRs, 
respectively.  
- Hypoglycaemia is considered a risk, in the EU and in the U.S., when used with a SU or 
basal insulin. Regarding the PT chart, it is possible to see that hypoglycaemia is the 3rd 
ADR most frequently reported with LYXUMIA.  
- In the EU, systemic hypersensitivity reactions were identified as important identified 
risks. For ADLYXIN, in the U.S., hypersensitivity was also considered a risk. According 
to the post-marketing available data, hypersensitivity remains in the top 10 of the most 
reported ADRs.  
- CV events were considered potential risks for this medicinal product just in the EU. 
When analysing the post-marketing data, it is possible to realize that, up to the 
moment, the occurrence of such events is not higher, as the Cardiac disorder SOC has 
only 12 cases reported. 
- Acute pancreatitis belongs to the list of potential risks associated with the use of 
LYXUMIA, in the EU. Similarly, in the U.S. pancreatitis is also considered a risk. 
According to the PT chart, up to July 2016 there were 6 cases of pancreatitis and 6 of 
pancreatitis acute associated with the use of LYXUMIA.  
- Malignant neoplasms is a potential risks for this medicinal product. Per the SOC chart, 
the SOC Neoplasms benign, malignant and unspecified has a very low prevalence (4 
cases), being among the less reported, and there is no carcinoma PTs among the to 
35.  
- Immunogenicity/neutralization are considered potential risks for this medicinal product 
both in the EU and in the U.S.. Moreover, in the U.S. hypersensitivity reactions were 
also included in the risk list. Based on the charts results, this is not verified.  
- Acute renal impairment is an important potential risk in the EU.In the U.S. renal 
impairment in patients with severe GI reactions was also included as a risk. 
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Accordingly, to the data presented in the charts, these are verified as Renal and urinary 
disorders SOC have a moderate prevalence, and acute kidney injury presented 6 
cases.  
- Dehydration is also addressed as a potential risk only in the EU. Nevertheless, this PT 
is not presented among the 35 mostly reported.  
- Weight decreased is not identified as risk to LYXUMIA but it is presented in the top 35 
of the most reported PTs. Once this outcome is occurring in patients who use 
LYXUMIA, there was identified the potential risk off-label use in non-T2DM for weight 
loss. 
- Teratogenicity is also a potential risk in the EU. However, it is not corroborated by the 
post-marketing data, as no reports were identified in the SOC Congenital, familial and 
genetic disorders.  
- Blood glucose increased not considered as a risk, it has the 11th place of the most PTs 
reported. 
- Nervous system disorders SOC appears among the most prevalent SOCs. 
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EPERZAN/ TANZEUM 
The active substance of EPERZAN/TANZEUM is albiglutide, available in the pharmaceutical 
form of powder and solvent for solution for injection, administered subcutaneously once a 
week.  
Albiglutide is a GLP-1R agonist generated by fusion of GLP-1 analogue to albumin [28]. 
Albiglutide is produced in Saccaromyces cerevisiae by recombinant DNA technology. It is a 
recombinant fusion protein consisting of two copies of a 30-amino acid sequence of modified 
human GLP-1 genetically fused in series to human albumin (97% amino acid sequence 
homology to endogenous human GLP-1 fragment 7-36). The GLP-1 sequence has been 
modified to confer resistance to DPP-4 mediated proteolysis. The human albumin moiety of 
the recombinant fusion protein, together with the DPP-4 resistance, greatly extends the half-
life to 5 day allowing once weekly dosing [51].  
These medicinal product is approved in monotherapy and in several therapeutic 
combinations, as identified in Table 4 - Approved therapeutic indications. 
The following tables (Table 16 and Table 17) encompass the comparative analyses 
regarding the safety profile of EPERZAN, either between information included in EPAR and 
in RMP as well as between the safety concerns accepted by EMA and by FDA. 
Table 16 - Comparative analysis on EPERZAN' safety profile 
 Nonclinical data [51] Clinical data [51] RMP data [11] 
S
a
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ty
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n
c
e
rn
s
 
Toxicology 
Monkey: 
- No CV effects nor effects in 
respiratory function. 
- Increased pancreas weight 
(more in males than in 
females) and significant 
increase in islet cell number.  
 
Carcinogenicity 
- No carcinogenicity studies 
have been conducted due to 
immunogenicity: emergence of 
clearing anti-albiglutide 
antibodies by 14 days in 
rodents, meaningful 2-year 
studies in rats or mice are not 
feasible.  
Immune compromised mice. 
- A dose-dependent increase in 
plasma calcitonin levels (male 
and female): potential to cause 
C-cell hyperplasia and thyroid 
tumours in rodents. 
- Not suitable models: early 
decrease in systemic 
exposure. 
 
Reproduction toxicity 
- Mouse embryofoetal 
developmental: bent ribs (high 
dose)  
Important identified risks 
- Acute Pancreatitis  
- GI events  
- Hypoglycaemia  
- Injection Site Reactions  
- Immunogenicity  
- Pneumonia  
- Atrial fibrillation/flutter  
 
Important potential risks 
- CV safety of antidiabetic therapy  
- Medullary Thyroid Cancer 
(Thyroid C-cell Tumours 
nonclinical)  
- Hepatotoxicity  
- Pancreatic cancers  
- Intestinal Obstruction  
- Foetal & neonatal 
developmental toxicity-
nonclinical  
- Accelerated sexual maturation 
(based on nonclinical)  
 
- Missing information 
- Use in pregnancy and lactation  
- Use in paediatric population  
- Use in hepatic impairment  
- Use in very elderly (age ≥ 75 
years)  
- Use in severe renal impairment 
(eGFR < 30 ml/ by MDRD)  
- Use in NYHA Class III/ IV heart 
failure 
Important identified risks 
- Acute Pancreatitis  
- GI events  
- Hypoglycaemia  
- Injection Site Reactions  
- Immunogenicity  
- Pneumonia  
- Atrial fibrillation/flutter  
 
Important potential risks 
- CV safety  
- Medullary Thyroid Cancer (Thyroid 
C-cell Tumours nonclinical)  
- Hepatotoxicity  
- Pancreatic cancers  
- Malignant neoplasms following 
combination treatment with insulin 
- Foetal & neonatal developmental 
toxicity (nonclinical) 
- Accelerated sexual maturation 
(nonclinical)  
 
- Missing information 
- Use in pregnancy and lactation  
- Use in paediatric population  
- Use in hepatic impairment  
- Use in very elderly (age ≥ 75 
years)  
- Use in severe renal impairment 
(eGFR < 30 ml/ by MDRD)  
- Use in NYHA Class III/ IV heart 
failure 
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Table 17 - Summary of safety concerns considered by EMA and FDA for EPERZAN and TANZEUM, respectively. 
 EMA FDA [52] [53] 
S
a
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ty
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o
n
c
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Important identified risks 
- Acute Pancreatitis  
- GI events  
- Hypoglycaemia  
- Injection Site Reactions  
- Immunogenicity  
- Pneumonia  
- Atrial fibrillation/flutter  
 
Important potential risks 
- CV safety  
- Medullary Thyroid Cancer (Thyroid C-cell Tumours nonclinical)  
- Hepatotoxicity  
- Pancreatic cancers  
- Malignant neoplasms following combination treatment with 
insulin 
- Foetal and neonatal developmental toxicity (nonclinical) 
- Accelerated sexual maturation in juveniles (nonclinical) 
 
Missing information 
- Use in pregnancy and lactation  
- Use in paediatric population  
- Use in hepatic impairment  
- Use in very elderly (age ≥ 75 years)  
- Use in severe renal impairment (eGFR < 30 ml/ by MDRD)  
- Use in NYHA Class III/ IV heart failure 
- Acute Pancreatitis 
- GI events (e.g., nausea, vomiting, 
diarrhoea) 
- Increased hypoglycaemia in 
combination with drugs known to 
cause hypoglycaemia (SU and 
insulin) 
- Injection Site Reactions, e.g., 
hematoma, erythema, rash, 
hypersensitivity. 
- Pneumonia 
- Atrial fibrillation/Atrial flutter 
- Medullary thyroid cancer 
- CV safety 
- Immunogenicity, e.g., clinical 
sequelae of antidrug antibodies, 
severe hypersensitivity reactions, 
other immune related events 
- Hepatotoxicity 
- Use in pregnancy and lactation 
- Use in paediatric population 
- Use in patients with hepatic 
impairment 
- Worsening renal function precipitated 
by dehydration due to product related 
GI adverse reactions 
 
The post-marketing data, meaning the ADRs reported in EU and U.S., are presented in 
individual charts. Additionally, a comparison of adverse reactions reported both in EU and 
U.S., grouped by SOC, can be seen in a chart format.  
 
- European database of suspected adverse drug reaction reports  
The data herein presented was retrieved from European database adrreports.eu [36]. This 
website gives access to web reports on suspected ADRs by medicine or by active substance 
name. All data displayed in the web reports is taken from EudraVigilance, a system designed 
for collecting reports of ADRs occurred within and outside the EEA [36]. This includes reports 
received from healthcare professionals and patients, reported by national competent 
authorities and MAHs. 
The following charts (Chart 21 and Chart 22) illustrate the number of the ADRs reported up 
to July 2016 to EudraVigilance, grouped by SOC and by PT, respectively.  
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Chart 21 - Number of Individual Cases by Reaction Groups sorted by Geographic Origin in EU for EPERZAN 
 
 
Chart 22 - Adverse Events reported in EU for EPERZAN grouped by PT 
 
- FDA Adverse Events Reporting System (FAERS) Data 
(DrugCite.com) 
This database includes information regarding the number of the ADRs reported since the 
authorisation date up to the Q3 2012 to FDA. As TANZEUM was only approved in 2014 in 
U.S., there is no data available yet.  
 
- Comparison of adverse events reported in EU and U.S., 
grouped by SOC 
As no data is available from FDA, it was not possible to perform this comparison.  
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It is not possible to perform a comparison between the post-marketing data in the EU and in 
the U.S., as no U.S. data are available. However, on the basis of the charts and tables 
previously presented, it is possible to perform the following analysis:  
- In respect to the pre-marketing identified safety concerns, the main differences 
between the EU and the U.S. reside on pancreatic cancers, malignant neoplasms 
following combination treatment with insulin, foetal and neonatal development toxicity 
and accelerated sexual maturation in juveniles, which were identified in the EU as 
potential risks but not in the U.S.. 
- Regarding the safety concerns identified in the phase pre-marketing and the results 
obtained in the post-marketing and here presented in chart format, it is not possible to 
draw any analysis and/or conclusions, as the published data is not enough to enable it.  
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TRULICITY 
TRULICITY is a new long acting human GLP-1R agonist containing dulaglutide as active 
substance. Dulaglutide is a disulfide-bonded covalent homodimer fusion protein encoded by 
a single synthetic gene. The gene for dulaglutide contains the GLP-1 analogue, linker and an 
engineered human immunoglobulin G4 (IgG4) heavy chain fragment (Fc) domain. This 
means, Dulaglutide molecule consists of 2 identical disulfide-linked chains, each containing a 
human GLP-1 analogue sequence covalently linked to a modified human IgG4 Fc by a small 
peptide linker. The GLP-1 analogue portion of dulaglutide is approximately 90% homologous 
to native human GLP-1 with amino acid substitutions aiming at optimizing its solubility and 
pharmacological activity, including protection from DPP-4 inactivation and reduced 
immunogenicity. The IgG-Fc increases the size of the molecule, therefore reducing the rate 
of clearance. The IgG4 Fc portion of the molecule was also modified to prevent half-antibody 
formation and to reduce the potential for interaction with high affinity Fc receptors that may 
result in immunologic cytotoxicity. The pharmacokinetic profile of dulaglutide suggests a 
plasma half-life (t1/2) of approximately 4.7 days, which makes it suitable for once weekly 
administration [30, 40]. 
Dulaglutide is a clear, colourless solution for injection and is available as a prefilled syringe 
(PFS) and a prefilled pen, each for single use only. Dulaglutide is available in two strengths: 
0.75 mg in 0.5 ml solution, and 1.5 mg in 0.5 ml solution. For monotherapy, the 
recommended dose is 0.75 mg once weekly by SC injection. For add-on therapy the 
recommended dose is 1.5 mg once weekly [40].  
These medicinal product is approved in monotherapy and in several therapeutic 
combinations, as identified in Table 4 - Approved therapeutic indications. 
Regarding the TRULICITY’ safety profile, comparative analyses are presented. A 
comparison between safety information included in EPAR (nonclinical and clinical data) and 
in RMP is illustrated in Table 18. Table 19 resumes the safety concerns considered by EMA and 
those ones accepted by FDA.  
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Table 18 - Comparative analysis on TRULICITY’ safety profile 
 Nonclinical data [30] Clinical data [30] RMP data [40] 
S
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Monkey: 
- Ani-drug antibodies not detected 
- QTc prolongation observed (higher doses than 
the proposed clinically) 
 
Toxicology 
Rat: 
- No pancreatic inflammation, necrosis, 
hyperplasia or neoplasia (58-fold the 
maximum recommended human dose 
[MRHD]) 
Monkey: 
- No thyroid C-cell neoplasia or pancreatic 
inflammation, necrosis, hyperplasia, or 
neoplasia (474-fold the MRHD). 
 
Carcinogenicity 
Transgenic mice: 
- No thyroid C-cell neoplasia or pancreatic 
inflammation, necrosis, hyperplasia, or 
neoplasia (4-fold the MRHD) 
Rat: 
- Non-fatal, thyroid C-cell tumours (≥ 7-fold the 
MRHD).  
- C-cell carcinomas were noted 
- No pancreatic inflammation, necrosis, 
hyperplasia or neoplasia (58-fold the MRHD). 
Non-diabetic rat: 
- Increased focal thyroid C-cell hyperplasia 
(chronic treatment) 
- Not increase diffuse C-cell hyperplasia or 
basal or calcium chloride-stimulated plasma 
calcitonin. 
 
Reproduction Toxicity 
Rat / Rabbit 
- Embryofoetal development studies: skeletal 
effects were noted and memory deficits were 
observed.  
Important Identified 
Risks 
- Hypoglycaemia  
- Acute pancreatitis  
- GI events  
 
Important Potential Risks  
- Hypersensitivity  
- Thyroid C-cell tumours  
- Pancreatic malignancy  
- CV effects  
- Medication errors (more 
than one injection per 
week)  
 
Missing Information  
- Use in children and 
adolescents <18 years of 
age  
- Use in pregnant and/or 
breastfeeding women  
- Use in patients with 
hepatic impairment  
- Use in patients with 
severe renal failure  
- Use in patients with 
congestive heart failure  
- Use in patients aged ≥75 
years  
- Confirmation of memory 
deficits in directly dosed 
immature rats 
Important Identified 
Risks:  
- Hypoglycaemia 
- Acute pancreatitis 
- GI events 
 
Important Potential 
risks 
- Hypersensitivity 
- Thyroid C-cell Tumours 
- Pancreatic malignancy 
- CV effects 
- Medication Errors 
(more than one 
injection per week) 
 
Missing Information  
- Use in children and 
adolescents <18 years 
of age  
- Use in pregnant and/or 
breastfeeding women  
- Use in patients with 
hepatic impairment  
- Use in patients with 
severe renal failure  
- Use in patients with 
congestive heart failure  
- Use in patients aged 
≥75 years  
- Confirmation of 
memory deficits in 
directly dosed 
immature rats 
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Table 19 - Summary of safety concerns considered by EMA and FDA for TRULICITY 
 EMA FDA [54, 55] 
S
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Important Identified Risks:  
- Hypoglycaemia 
- Acute pancreatitis 
- GI events 
 
Important Potential risks 
- Hypersensitivity 
- Thyroid C-cell Tumours 
- Pancreatic malignancy 
- CV effects 
- Medication Errors (more than one injection per week) 
 
Missing Information  
- Use in children and adolescents <18 years of age  
- Use in pregnant and/or breastfeeding women  
- Use in patients with hepatic impairment  
- Use in patients with severe renal failure  
- Use in patients with congestive heart failure  
- Use in patients aged ≥75 years  
- Confirmation of memory deficits in directly dosed immature 
rats 
- Increased hypoglycaemia in 
combination with drugs known to 
cause hypoglycaemia (SU and 
insulin) 
- Acute pancreatitis 
- GI reactions, e.g. diarrhoea, nausea 
and vomiting; 
- Hypersensitivity reactions 
- Thyroid c-cell tumours, including 
medullary thyroid cancer 
- Pancreatic cancer 
- CV events (e.g. increased heart rate) 
- Immunogenicity, i.e. anti-dulaglutide 
antibodies 
- Worsening renal function precipitated 
by dehydration due to product related 
GI adverse reactions 
 
- European database of suspected adverse drug reaction reports  
The data herein presented was retrieved from European database adrreports.eu [36]. This 
website gives access to web reports on suspected ADRs by medicine or by active substance 
name. All the data displayed in the web reports is taken from EudraVigilance, a system 
designed for collecting reports of ADRs occurred within and outside the EEA [36]. This 
includes reports received from healthcare professionals and patients, reported by national 
competent authorities and MAHs. 
The following charts (Chart 23 and Chart 24) illustrate the number of the ADRs reported for 
TRULICITY up to July 2016 to EudraVigilance, grouped by SOC and by PT, respectively.  
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Chart 23 - Number of Individual Cases by Reaction Groups sorted by Geographic Origin in EU for TRULICITY 
 
 
Chart 24 - Adverse Events reported in EU for TRULICITY grouped by PT 
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- FDA Adverse Events Reporting System (FAERS) Data 
(DrugCite.com) 
This database includes information regarding the number of the ADRs reported since the 
authorisation date up to the Q3 2012 to FDA. As TRULICITY was only approved in 2014 in 
U.S., there is no data available yet.  
- Comparison of adverse events reported in EU and U.S., 
grouped by SOC 
As no data is available from FDA, it was not possible to perform this comparison.  
 
It is not possible to perform a comparison between the post-marketing data in the EU and in 
the U.S., as no U.S. data are available. However, on the basis of the charts and tables 
previously presented, it is possible to perform the following analysis:  
- Hypoglycaemia is considered a risk both in the EU and in the U.S.. Hypoglycaemia and 
blood glucose decreased have been reported in the EU. 
- Acute Pancreatitis belong to the list of risks associated with the use of dulaglutide, both 
in the EU not in the U.S.. This risk is corroborated by the real world data, since 
represents the ADR most reported in the EU, with a very high prevalence.  
- GI AEs, such as diarrhoea, nausea and vomiting, are identified risks associated with 
this medicinal product. Accordingly, GI disorder SOC is the SOC with the major number 
of cases reported in the EU, being nausea, vomiting and diarrhoea, after pancreatitis, 
the most reported ADRs. 
- Hypersensitivity reactions were identified in the pre-marketing phase as being risks for 
this medicinal product both in the EU and in the U.S.. Nevertheless, by the analysis of 
the PT chart it is possible to realise that hypersensitivity reactions are not presented 
among the 35 reactions most reported. Additionally, the SOC Immune system 
disorders is one of those with less cases reported.  
- Pancreatic cancers and thyroid C-cell tumours are considered risks in the EU and in 
the U.S.. The SOC Neoplasms benign, malignant and unspecified is among those ones 
with less reports in the EU. Moreover, concerning the PTs charts, no carcinomas are 
presented in the 35 most reported reactions.  
- CV events were considered potential risks for this medicinal product in the both 
geographical areas. The SOC Cardiac disorders is on the 6th position of prevalence in 
the EU, and what concerns to the PTs there are some cardiac reactions presented in 
the 35 most reported ADRs, such as myocardial infarction, arrhythmia and palpitations.  
- Decreased renal function and dehydration are identified as risks in the U.S.. In 
accordance with the data presented in the charts, these are verified as Renal and 
urinary disorders SOC have a moderate prevalence, occupying the 7th position in the 
SOC chart. Also in the PT chart, dehydration is 4th reaction most reported and acute 
kidney injury and renal failure are presented among the top 20 of the most reported 
ADRs.  
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- Immunogenicity (anti-dulaglutide antibodies) is identified as risk in the U.S., but not in 
the EU. On the basis of the charts results, this is not verified in the EU post-marketing 
data.  
- Weight decreased is not identified as risk but it 5th reaction most reported.  
- Blood glucose increased not considered as a risk, it has the 9th position of the most 
PTs reported. 
- Nervous system disorders SOC appears among the most prevalent SOCs, being the 
5th with most prevalence.  
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Discussion 
Despite GLP-1R agonists are authorised in Europe since 2006 (BYETTA’S approval year), in 
Portugal only in 2014 the first GLP-1R agonists were reimbursed. The reimbursement was 
approved for VICTOZA in January 2014 and for BYDUREON in October 2014. BYETTA’S 
reimbursement request was rejected not showing therapeutic nor economic advantage. In 
coming years, it is expected that several other GLP-1 agonists become reimbursed. The 
post-marketing experience gathered by other countries, both in Europe and U.S., is of most 
importance, as it enables to draw a more accurate safety profile for these medicines and 
allows deducing which will be the most serious adverse reactions to be expected in 
Portuguese patients using these medicinal products.  
At an initial stage, only BYETTA, VICTOZA and BYDUREON were included in the analysis, 
since they were the first GLP-1R agonists approved for T2DM both in the EU and in the U.S., 
and for which the reimbursement had been requested in Portugal. Nevertheless, and as 
observed in Table 2 - GLP-1R agonists approved in EU and Table 3 - GLP-1R agonists 
approved in U.S., there are other three medicinal products (LYXUMIA/ADLYXIN, 
EPERZAN/TANZEUM and TRULICITY) approved in the EU and in the U.S.. As the main 
goals of the present work are drawing a safety profile for GLP-1R agonists and conclude on 
the need and/or opportunity of adapting the RMP for the new markets, taking into account 
the safety data collected both in the EU and in the U.S., include LYXUMIA/ADLYXIN, 
EPERZAN/TANZEUM and TRULICITY in this evaluation seem to be a real asset. 
By the results presented previously, it was noticeable that there were some discrepancies, 
not only between the safety concerns identified in the EU and in the U.S. for the same 
medicinal products but also there are differences in the safety concerns identified among the 
several medicinal products.  
Following specific analysis performed for each medicinal product, the Table 20 and Table 21 
intend to present a global picture of the safety profile of the GLP-1R agonists class. The first 
presents all the medicinal products with their respective safety concerns identified in the pre-
marketing phase and the last provides the ranking of the most prevalent SOCs for this 
pharmacological class. For comparison purposes, there was the need to choose a common 
data set and, for that reason and as no complete U.S. data is available for 
LYXUMIA/ADLYXIN, EPERZAN/TANZEUM and TRULICITY, both tables comprise the EU 
pre- and post-marketing data, respectively. 
A thorough analysis of each SOC considered relevant to the present work will be also 
presented in this section. Moreover, whenever considered applicable, a specific safety 
concern may be specifically addressed in this analysis, instead of analysing the SOC in 
general. The concerned analysis will include all the data results presented in the RESULTS 
section as well as will refers to the data presented in the tables provided below.  
 
 
  
Table 20 - Comparison of safety concerns identified for all GLP-1R agonist (pre-marketing EU data) 
 
 
Exenatid
e 
Exenatide-
extended 
release 
Albiglutide Dulaglutide Liraglutide Lixisenatide 
Im
p
o
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a
n
t 
Id
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R
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Pancreatitis  
 Hypoglycaemia 
Acute Renal failure  
Rapid Weight Loss 
 
 GI events (nausea, diarrhoea, vomiting, constipation and dyspepsia) 
 
 Hypersensitivity 
 
Injection Site Reactions    
 
Immunogenicity 
 
 
Pneumonia 
 
 
Atrial fibrillation/flutter 
 
Im
p
o
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a
n
t 
P
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n
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l 
R
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Cardiovascular effects / Cardiac co-morbidity 
  Hypersensitivity / Immunogenicity (antibodies) 
Thyroid Neoplasms 
Pancreatic cancers  
 Pancreatitis (acute) 
Malignant Neoplasms  Malignant Neoplasms 
 Hepatotoxicity  
 
Foetal & neonatal 
developmental toxicity 
 Teratogenicity 
 Medication Errors  
 
Late stage microvascular eye 
complication 
 
 Dehydration 
 Acute renal impairment 
 Off-label use (weight loss) 
M
is
s
in
g
 I
n
fo
rm
a
ti
o
n
 
Use in children and adolescents <18 years of age 
Use in pregnancy and/or lactation 
Use in very elderly (age ≥ 75 years)   
Potential for Concomitant 
use with TZDs 
 
 Use in patients with moderate and severe renal impairment 
 Use in patients with hepatic impairment  
 
Severe GI 
disease 
 
 Use in patients with congestive heart failure  
 Memory deficits (rats)  
 Overdose  
 Abuse due to weight lowering potential  
 Drug-drug interaction with warfarin  
 
Off-label use 
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Table 21 - Comparison of most prevalent SOCs for all GLP-1R agonist (post-marketing EU data) 
MedDRA 19.0 
System Organ Class (SOC) 
Post-Marketing EU data – rating of AEs mostly reported 
BYETTA BYUDUREON VICTOZA LYXUMIA TRULICITY EPERZAN 
Cardiac disorders 11th 11th  9th  10th  6th - 
Gastrointestinal disorders 1st 1st 1st 1st  1st - 
General disorders and 
administration site conditions 
4th 2nd  4th  3rd  4th 1st 
Hepatobiliary disorders 10th 18th  8th  13th  14th - 
Immune system disorders 20th 14th  19th  12th  16th - 
Infections and infestations 9th 8th  10th  7th  9th - 
Injury, poisoning and 
procedural complications 
5th 4th  11th  8th  8th - 
Investigations 2nd 3rd  3rd 4th  2nd - 
Metabolism and nutrition 
disorders 
6th 6th  5th  2nd  3rd 1st 
Neoplasms benign, malignant 
and unspecified (incl cysts 
and polyps) 
3rd 9th  2nd  17th  17th - 
Nervous system disorders 8th 5th  6th  5th  5th 1st 
Renal and urinary disorders 7th 13th  7th  9th  7th - 
Respiratory, thoracic and 
mediastinal disorders 
12th 10th  13th  11th  12th - 
Skin and subcutaneous tissue 
disorders 
14th 7th  12th  6th  10th - 
Note: The colours represent the ranking of reported AEs. RED represents the mostly reported and GREEN the 
least reported AEs.  
 
As observed in the table above, for EPERZAN there is no relevant data in the post-marketing 
environment. Therefore, in the analysis presented below, associated with the post-marketing 
data, whenever “all medicinal products” are referred this medicinal product is not included.  
 
CARDIAC DISORDERS SOC 
Patients with T2DM have a several-fold increased risk of developing CV disease when 
compared with nondiabetic controls [56]. GLP-1R was detected in cardiac and vascular 
tissues and GLP-1R protein was also detected in human coronary artery endothelial cells 
and human umbilical vein endothelial cells [56]. The effect of GLP-1R agonists on heart 
failure remains uncertain [57]. Animal studies have shown that the GLP-1R agonist liraglutide 
can activate cytoprotective pathways in the heart, and improve outcomes after experimental 
myocardial infarction in mice. Early clinical studies also suggested that GLP-1R agonists 
have positive effects on CV biomarkers, such as high-sensitivity C-reactive protein and 
plasminogen activator inhibitor-1, and improve regional and overall left ventricular function in 
patients with acute myocardial infarction and severe systolic dysfunction after successful 
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primary angioplasty [57]. Li L, et al [57], based on their findings, concluded that the current 
evidence suggests that GLP-1R agonists do not increase the risk of heart failure or 
hospitalization for heart failure. The current body of evidence, however, is not definitive. 
An increase in heart rate, independent risk factor for cardiac mortality, accompanied by a 
decrease in blood pressure has been reported during treatment with liraglutide and 
exenatide. The mechanism behind the change in heart rate is not known, but might involve 
increased natriuresis and lowered blood pressure. Whether the benefit of the decrease in 
blood pressure outweighs the harm of the increase in heart rate remains to be determined. 
Several large CV outcome trials (LEADER (liraglutide), EXSCEL (exenatide once-weekly), 
ELIXA (lixisenatide), REWIND (dulaglutide)) including up to 9,500 patients with T2DM are 
ongoing and are expected to be completed between 2016 and 2019 [58]. When the results 
from these trials are available, there will be more definitive answers on the relationship 
between GLP-1R agonists and CV safety [59, 60]. 
Regarding Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study, American 
Diabetes Association stated that no increased risk for CV death, heart attack, stroke, 
unstable angina or heart failure was found in people with T2DM who had recently 
experienced acute coronary syndrome events and were therefore at high risk for additional 
heart problems. The study examined 6,068 people from 49 countries, randomly assigning 
them to lixisenatide or placebo, with a follow-up period of more than two years [61]. 
A recent press release for the Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results (LEADER) trial investigating the CV safety of the GLP-1R 
agonist, stated that liraglutide reports reduced CV risk assessed by the composite outcome 
of the first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke [62]. 
Overall, GLP-1R agonists have demonstrated positive CV outcomes with slight 
improvements in blood pressure and lipid parameters and modest improvements in weight. 
According to Prasad-Reddy L. et al, a meta-analysis of 33 trials consisting of exenatide twice 
daily, exenatide weekly, liraglutide, and albiglutide showed no increase in major CV events, 
including myocardial infarctions, strokes, and all-cause mortality, when compared to other 
agents or placebo. Thus far, studies and post-marketing reports with exenatide and 
liraglutide have not demonstrated any prolongation of the QT interval [59]. 
On the basis of the data presented in the previous section, CV effects or cardiac co-morbidity 
were identified in the EU during the pre-marketing phase as potential risks for all the 
medicinal products under analysis. Additionally, atrial fibrillation and atrial flutter were also 
classified as important identified risks for EPERZAN.  
Referring to the U.S., the CV events were also considered safety risks associated with the 
use of these medicinal products, excepting for BYETTA and for ADLYXIN. Similar to the EU, 
for EPERZAN atrial fibrillation and atrial flutter were also considered risks.  
Regarding the real-world data, is possible to realize that for the majority of the medicinal 
products the Cardiac disorders SOC is not one of the most prevalent. Nevertheless, for 
BYDUREON and TRULICITY, in the U.S. and in the EU respectively, this SOC occupies the 
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6th position in the ranking of the most prevalent, being myocardial infarction, palpitations, 
atrial fibrillation and arrhythmia among the 35th most reported PTs. 
 
According to the aforementioned information, it is possible to conclude that the CV risk is not 
fully clarified nor completely linked to the GLP-1R agonist class. Therefore, and taking into 
account all the minimisation measures implemented for all the medicinal products concerned, 
CV risks should be continuously considered as important potential risks associated with this 
therapeutic class.  
Large multicentered studies are currently underway, to confirm the CV safety use of incretins 
in subjects with T2DM. These studies will allow to get a better understanding on CV effects 
of the GLP-1R agonists.  
 
GASTROINTESTINAL DISORDERS SOC 
In the EU, GI events, such as nausea, diarrhoea and vomiting, were included in the important 
identified risks for all medicinal products except for the exenatide-containing medicines, 
BYETTA and BYDUREON. Severe GI disease was considered missing information related to 
the use of BYDUREON. In the U.S., these events were also associated with the use of the all 
GLP-1R agonists class.  
The PT pancreatitis also belongs to the GI disorders SOC. This ADR is classified as 
important identified risk to the BYETTA, BYDUREON, EPERZAN and TRULICITY, and it was 
considered potential risk for VICTOZA and LYXUMIA, in the EU. Concerning the U.S., 
pancreatitis was identified as risk for all GLP-1R agonists, except for BYETTA.  
Clinical trials with GLP-1R agonists have reported the most frequently reported treatment-
related AE about GLP-1 RAs was GI disorders, mainly nausea, vomiting, and diarrhoea. 
Some research has shown that the GI AEs associated with GLP-1 RAs are dose dependent 
and decline over time [63-65]. Delayed gastric emptying will lead to gastrointestinal 
symptoms, such as early satiety, postprandial fullness, epigastric pain, nausea, and vomiting. 
Although these GI symptoms are not considered to be important causes of mortality in 
T2DM, they have obvious negative influences on diabetes control, diabetes complications, 
and health-related quality of life [58, 59, 63].  
The incidence of acute pancreatitis is increased in the background T2DM population, 
possibly because of the coexistence of occult exocrine pancreatic abnormalities in the 
diabetic population, or possibly because of a high prevalence of obesity and gallstones. Most 
studies have not confirmed an increased incidence of acute pancreatitis with GLP-1R agonist 
therapy, but these lacked the statistical power to exclude a smaller effect (e.g. up to 2-fold 
increase) [58, 64, 65]. 
When exenatide twice daily first became available, there was reporting of exenatide-induced 
pancreatitis. This led the FDA to release a warning referring that post-marketing studies of 
exenatide may suggest a link between treatment and acute pancreatitis, and that healthcare 
professionals should monitor for signs of pancreatitis in patients using these agents [59].  
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Over time, several assessments of pancreatitis-related to GLP-1R agonists have been 
performed by EMA. In 2013, EMA was made aware of findings by a group of academic 
researchers suggesting an increased risk of pancreatitis and cellular changes in patients 
treated for T2DM with GLP-1 based therapies. The investigators described a number of 
findings in the pancreata of the T2DM individuals treated with these medicines which could 
implicate an association of the treatment with increased risk of pancreatitis and neoplasms 
[66].  
A significant number of cases were observed and a causal relationship between GLP-1 
based therapy treatment and pancreatitis was considered possible. Warnings were already 
included in the product information for all products, albeit with small differences in the 
wording, and pancreatitis was being followed in the periodic safety update reports as well as 
in observational and randomised clinical trials. Therefore, EMA concluded that these actions 
were sufficient and no new data had emerged that implies that this risk is higher compared to 
what had previously been concluded. However, with the next updates of the RMPs, 
pancreatitis, which should be already mentioned in the RMPs as a potential risk should be 
listed as an identified risk for all products and it would be appropriate to harmonize the 
wording of the warning with respect to a recommendation to use the products with caution in 
patients with a history of pancreatitis as well as a recommendation not to resume treatment if 
pancreatitis has occurred [66]. In conclusion, according to Pharmacovigilance Risk 
Assessment Committee (PRAC) recommendation, the results of the study by Butler et al 
were not considered to constitute a new safety signal for the GLP 1 based therapies with 
respect to pancreatic safety. This was further supported by the review of available preclinical 
and clinical data. However, due to the mechanism of action, there were still some 
uncertainties with respect to long term pancreatic safety associated with these products and 
updates to the RMPs (including planned and ongoing studies) and harmonisation of warnings 
in the product information were taken forward [66]. 
In the post-marketing presented in the previous section, GI disorders is the mostly reported 
SOC in all medicinal products (1st place in the ranking).  
Regarding nausea, diarrhoea and vomiting it is easily observed that these adverse reactions 
belong to the top 10 of the mostly reported for almost all the medicinal products either in the 
EU or in the U.S.. A single difference remains in BYDUREON, in the U.S., for which vomiting 
is not included in the top 10 but it occupies the 19th position.  
Concerning pancreatitis, by the analysing of the PT charts of each medicinal product, it is 
observed that for BYETTA, VICTOZA and TRULICITY this adverse reaction appears as the 
mostly reported (1st position), as per the EU data. BYDUREON also presents a high rate of 
pancreatitis once it appears in the 2nd position of the mostly reported. LYXUMIA is the 
medicinal product with less prevalence of this adverse reaction, in which this reaction has the 
13th place of the ranking. Other forms of pancreatitis are also reported, such as pancreatitis 
acute or chronic. It seems important to highlight the occurrence of pancreatitis associated 
with VICTOZA, as pancreatitis occupies the 1st place in the mostly reported chart and 
pancreatitis acute has the 3rd one. This medicinal product presents the high prevalence of 
pancreatitis among all the GLP-1R agonists class.  
When comparing the data obtained in the EU and that in the U.S., it is realized that in the 
U.S. the prevalence of occurrence such adverse reaction is lower than in the EU.  
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According to the aforementioned information, it is possible to conclude that the GI events, 
such as nausea, vomiting and diarrhoea, are directly linked to the use of the GLP-1R 
agonists, as they were identified and prevalent for all medicines in this therapeutic class.  
Pancreatitis is also a safety concern linked to the utilisation of these medicinal products 
having a high prevalence in all the medicinal products mainly with VICTOZA. Hence, this 
safety concern should be considered a class effect and should be classified as important 
identified risk for all GLP1-R agonists.  
 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS SOC 
This concerned SOC comprises several adverse reactions affecting patient’s general well-
being, such as malaise, asthenia, fatigue and pain, as well as adverse reactions associated 
with the drug administration site.  
These kind of reactions were not identified as risk for all the medicinal products. In the EU, 
injection site reactions were only considered as potential risk for VICTOZA and were 
classified as important identified risk for EPERZAN.  
Regarding the U.S., injection site nodules and reactions were identified as risk for 
BYDUREON and injection site reactions were also considered risks for VICTOZA and 
TANZEUM. 
In the literature it was also found some data identifying that injection-site reactions were 
more common with the once weekly formulation, which is expected, as symptoms, 
particularly itching, have been shown to have a higher incidence with injectable sustained-
release products that degrade over time in the body [60]. Exenatide once weekly had higher 
reporting of injection site reactions, including nodule formation after injection [60]. Injection-
site reactions may be more common with the longer acting agents, particularly exenatide 
once weekly which can cause transient small nodules at the injection site. However, patient 
satisfaction data indicate that once weekly injections result in higher patient satisfaction 
compared with twice daily injections[65]. 
According to Table 21 presented at the beginning of this section, General disorders and 
administration site conditions SOC is the 3rd with most prevalence, being in the 2nd place of 
the ranking for BYDUREON, the 3rd for LYXUMIA and the 4th for the remaining medicinal 
products. 
Based on the data available regarding the top 35 of adverse reactions reported in the global 
population, general disorders, for instance malaise, asthenia and fatigue, are presented in 
this top in general for all medicinal products, both in the EU and in the U.S., whenever 
applicable. 
As BYETTA and BYDUREON have the same active substance, it was expected that both of 
them had a similar safety profile. Still, it is not verified as some slight differences are 
observed either in Chart 11 or in Chart 12 and Chart 13. One example of these discrepancies 
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is the prevalence of this concerned SOC, once it is more prevalent with BYDUREON than 
with BYETTA. According to data displayed in Chart 13 it is possible to realize that 
BYDUREON presents much more reports of site administration reactions than BYETTA. 
Therefore, the pre-marketing data is in accordance with the post-marketing data presented 
throughout this work, and these findings are in agreement with the scientific information 
published in the literature.  
 
IMMUNE SYSTEM DISORDERS SOC 
Hypersensitivity reactions, most of times as anaphylactic-type reactions, and immunogenicity 
were associated with all the medicinal products under analysis. The occurrence of such 
reactions was closely linked to the occurrence of anti-drug antibodies.  
In the EU, on one hand, immunogenicity was classified as important potential risks for all 
medicines, excepting for EPERZAN, for which these reactions were considered important 
identified risks, and for TRULICITY, for which this reaction was not included in the risks. On 
the other hand, hypersensitivity was considered important potential risks for all except 
LYXUMIA and for EPERZAN, for which this reaction was included in the important identified 
risks and was not included in the risks, respectively.  
Concerning the U.S., both immunogenicity and hypersensitivity reactions were linked to all 
the medicinal products, being identified as risks for all of them.  
GLP-1R agonists are therapeutic peptides and, therefore, there is concern that antidrug 
antibodies could develop leading to decreased efficacy or to local or systemic 
hypersensitivity and neutralization over time [58, 59, 65, 67]. Antibody levels have been 
measured in clinical trials, with significant variation between the various GLP-1R agonists, 
which is thought to be due to differences in immunogenicity of the formulations. Newer 
formulations, including albiglutide and dulaglutide, have less risk of antibody formation 
compared to exenatide and liraglutide [59, 65, 67]. Exenatide produces the most antibodies 
out of the marketed GLP-1R agonists, possibly due to the lower sequence identity of 
exenatide with native GLP-1. Among the two exenatide formulations, exenatide weekly 
produces more antibodies than exenatide twice daily. Higher rates of injection-site reactions 
were observed in patients with antibody-positive titers, but other adverse effects were not 
statistically different. Those with high antibody titers overall had a smaller improvement in 
hemoglobin A1C values; however, there was no correlation found in hemoglobin A1C values 
between patients with negative titers versus those with low titers. [58, 59] 
Table 21 shows that Immune system disorders SOC is not one of the mostly prevalent for 
none of the medicines. Nonetheless, LYXUMIA appears has being the one with the higher 
prevalence, followed by BYDUREON.  
The data available in the U.S. is in accordance with the results presented in the EU. The 
comparative charts of adverse events reported in the EU and in the U.S. grouped by SOC 
(Chart 5, Chart 10 and Chart 18) show that the prevalence of this SOC in the U.S. is similarly 
low.  
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Even though parenteral administration of GLP-1R agonists may trigger an immune response, 
the available post-marketing data shows that such adverse reactions in the general 
population, compared to other safety concerns, have not a high prevalence. Therefore, it is 
possible to conclude that this safety concern is adequately addressed for all medicinal 
products. 
 
INVESTIGATIONS SOC 
In this SOC are included only PTs representing investigation procedures and qualitative 
results. Therefore, the most relevant PTs under analysis in this SOC are weight decreased 
and blood glucose increased.  
As seen in Table 21, Investigations SOC is the 2nd most prevalent for this therapeutic class.  
- Weight decreased 
Despite having been observed in all the medicines, weight loss was an important identified 
risk considered only for BYETTA and BYDUREON, in the EU. At some point of the time, this 
effect had turned up into a beneficial outcome associated with the use of GLP-1R agonists. 
Thus, for VICTOZA and LYXUMIA the abuse due to weight lowering potential and off-label 
use for weight loss were addressed as missing information and important potential risk, 
respectively.  
In the U.S., no safety concerns related to weight loss due to use of this medicines were 
considered.  
GLP-1 decreases GI motility, which increases the time that nutrients can be absorbed. It also 
increases satiety, increases resting metabolic rate, and lowers plasma concentrations of free 
fatty acids. In patients with T2DM, GLP-1 is diminished. In a meta-analysis that included 21 
trials and 3395 participants randomly assigned to GLP-1R agonists compared with 3016 
participants in various different control groups of different diabetes treatment agents, all trials 
showed a reduction in weight, which ranged from –0.2 to –7.2 kg. Higher doses of GLP-1R 
agonists correlated with greater weight loss [59].  
It is hypothesized that the mechanism by which GLP-1R agonists induce weight loss might 
be related to multiple actions involving the brain and gastrointestinal tract, as suppressed 
appetite, reduced body fat, and improved endothelial function. Liraglutide is the first GLP-1R 
agonist specifically approved for weight loss in patients without a history of T2DM, with the 
brand name Saxenda® [59, 65, 68]. 
Besides its presence in the GI tract, GLP-1 is found in the central nervous system localized 
to neurons primarily in the nucleus of the solitary tract in the caudal brainstem. Neurons in 
the nucleus of the solitary tract that express GLP-1 send projections to several brain regions 
that take part in feeding behaviour and energy homeostasis. Thus, GLP-1R antagonists 
show broad metabolic effects, far beyond the glycaemic control, and represent effective 
therapies for T2DM [65]. 
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According to the post-marketing data analysed during this work, both in the EU and in the 
U.S., BYETTA and BYDUREON presented weight decreased as one of the mostly reported 
ADRs, as for BYETTA this reaction occupied the 2nd place in both areas and for BYDUREON 
it was in the 3rd and in the 2nd position in the EU and in the U.S., respectively. VICTOZA and 
TRULICITY also presented a higher prevalence for this PT, being in the 7th and 6th positions, 
respectively, in the EU. In the U.S. VICTOZA also presented this PT in the 5th position of the 
mostly reported adverse events. LYXUMIA, among all the medicines, is the one which 
presents a lower prevalence for weight decrease (26th position).  
 
GLP-1R agonists have been associated with significant weight loss in patients with diabetes, 
and a question of whether these agents could be used for weight loss in patients without 
diabetes was raised [68]. As previously stated, liraglutide is already approved for weight loss 
in patients without T2DM. Per the clinical and non-clinical data as well as per the post-
marketing information herein presented, GLP-1R agonists are effective in this condition and 
so the using of these medicinal products out of the approved indications may be a possibility. 
Therefore, off-label use for weight loss should be an important potential risk for all these 
medicines.  
- Blood glucose increased 
One of the most frustrating things that diabetics deal with is an unexpected rise in blood 
glucose overnight. Morning hyperglycaemia in diabetic subjects may be caused by the Dawn 
Phenomenon or the Somogyi Effect [69].  
The Dawn Phenomenon is a condition described in patients with diabetes mellitus that is 
characterized by abrupt increases in fasting levels of plasma glucose or insulin requirements 
or both, in the absence of antecedent hypoglycaemia [70]. According to Sheehan J, the 
pathogenesis of the Dawn Phenomenon may be tied to an exacerbation of the normal 
circadian variation in hepatic sensitivity to insulin observed in subjects without diabetes. 
Research suggests that this decrease in sensitivity is induced by the nocturnal secretion of 
growth hormone [71]. 
The Somogyi effect postulates that nocturnal hypoglycaemia causes fasting hyperglycaemia 
attributable to counterregulatory hormone release, namely glucagon, epinephrine, 
norepinephrine, growth hormone and cortisol [72, 73]. Bolli G et al, demonstrated that 
hypoglycaemia can cause rebound hyperglycaemia in the absence of the waning of insulin 
action and that this results primarily from an excessive increase in glucose production due to 
activation of glucose counterregulation by the antecedent hypoglycaemia. The concomitant 
waning of the effect of insulin, when it occurs, exacerbates posthypoglycaemic 
hyperglycaemia and increases the rapidity of its development [74]. The increase in 
counterregulatory hormones causes rapid mobilization of glucose from the liver and reduced 
insulin sensitivity decreasing peripheral tissue uptake of glucose. Because individuals with 
diabetes cannot counterbalance this glucose increase with endogenous insulin, rebound 
hyperglycaemia results [71].  
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The GLP-1R agonists are medicinal products with antidiabetic characteristics, so it was not 
expected that they lead to blood glucose increased, and so it was not addressed as a safety 
concern for these medicinal products.  
However, per the observed in the charts presented for each medicinal product in previous 
section (RESULTS), blood glucose increased was the mostly reported ADR linked to the use 
of GLP-1R agonists. For BYETTA and BYDUREON presented positions of 5th and 1st in the 
EU and in the U.S., respectively. For VICTOZA this PT in the EU occupied the 10th place and 
in the U.S. was in the 2nd one. LYXUMIA and TRULICITY presented slight lower prevalence 
with this PT in 11th and 9th positions respectively.  
 
By the aforementioned, the Somogyi effect could be the most possible cause of the 
hyperglycaemic ADRs reported, as these medicinal products are glucagon-based and this 
hormone is one of those which are involved in the Somogyi effect.  
 
METABOLISM AND NUTRITION DISORDERS SOC 
In this SOC the most relevant PTs under analysis are hypoglycaemia and dehydration.  
As seen in Table 21, Investigations SOC is the 4th most prevalent for this therapeutic class.  
- Hypoglycaemia  
In the EU, hypoglycaemia was considered an important identified risk for all the medicinal 
product apart from the exenatide-containing medicinal products (BYETTA and BYDUREON). 
This effect was linked to the use of GLP-1R agonists concomitantly with a SU or basal 
insulin, which are medicines known to cause hypoglycaemia.  
Similarly, in the U.S. hypoglycaemia when used together with a SU or basal insulin was also 
described as a safety concern for all GLP-1R agonists.  
One of the advantages of GLP-1 agonist administration is that insulin secretion is glucose-
dependent, and is inhibited at low glucose levels. This is an important safety feature since it 
means that, in contrast to injected insulin or sulfonylureas, insulin is no longer produced at 
low glucose levels. Use of the GLP-1 agonists in combination therapy may however 
aggravate the hypoglycaemic potential of the partner therapy [58]. The risk of hypoglycaemia 
is low with GLP-1R agonists and rates were similar across all GLP-1R agonists treatment 
groups, although the risk was increased with concomitant SU or insulin therapy [60, 64, 65].  
Regarding real world data, by the observation of the previous charts, in the EU this ADR was 
presented in the top 20 in all the medicinal products. However, this prevalence was not 
corroborated by data from the U.S..  
LYXUMIA, among all the other GLP-1R agonists, is the one which presents a higher 
prevalence of occurrence of this PT as it appears in the 3rd position of the mostly reported 
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
 
ANDREIA FILIPA RODRIGUES DOS SANTOS Page 79  
ADRs, according to the data retrieved from the European database of suspected adverse 
drug reaction reports website [36]. 
As identified in the pre-marketing phase, including nonclinical studies, hypoglycaemia may 
occur when these medicinal products are administered concomitantly with SU or insulin.  
- Dehydration 
Dehydration, in the EU, is a safety concern only addressed for LYXUMIA as important 
potential risk. Referring to the U.S., dehydration due to product related GI adverse reactions 
was included in the safety concerns for TANZEUM and TRULICITY.  
Patients with type 2 diabetes have an elevated risk for dehydration due to high glucose 
levels, and an increasingly popular class of diabetes drugs may increase this risk even more.  
Delayed gastric emptying can cause discomfort, nausea and vomiting; diarrhoea may also 
occur. Although these effects tend to diminish with time, and most patients find them 
tolerable, severe vomiting with dehydration may occur and precipitate pre-existing circulatory 
or renal disorders [58]. Many case reports of acute renal failure have been reported with the 
use of GLP-1 agonists, most likely triggered by dehydration from the gastrointestinal adverse 
effects—interpret vomiting and diarrhoea. Thus, it is recommended the cautious use of this 
drug class in patients with chronic kidney disease [65]. 
This ADR is presented in the top 35 of the most reported ADRs for all the medicines, except 
for LYXUMIA, in the EU and for VICTOZA in the U.S.. It is important to emphasise the 
prevalence of such reaction for VICTOZA and TRULICITY in the EU, for which dehydration 
occupies the 8th and the 5th position, respectively, in the ranking of the most reported PTs. 
As explained, dehydration is closely linked to the GI effects, namely vomiting and diarrhoea. 
As these are the most recognized effects associated with these medicines, dehydration 
occurs in patients with moderate prevalence. Additionally, the occurrence of dehydration 
might lead to a worsening in the renal function. Since this PT appears in the top 35 of the 
mostly reported ADRs for all medicines, and once this is not considered a risk for all 
medicinal products, maybe an harmonisation should be performed in order to include this risk 
in the RMPs of the medicinal products for which it is not stated.  
 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS) SOC 
This SOC is classified anatomically, with pathologic sub-classifications for staging of both 
benign and malignant neoplasms.  
In the EU (Medullary) Thyroid Neoplasms were addressed as important potential risk 
associated with the use of all medicinal products. Moreover, pancreatic cancers were also 
considered important potential risks for BYETTA, BYDUREON, EPERZAN and TRULICITY. 
Other malignant neoplasms were also classified as important potential risks for all medicinal 
products but TRULICITY.  
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Also, in the U.S. the malignancy risk was considered to the use of these medicinal products. 
The increased risk of medullary thyroid tumours associated with the use of GLP-1R agonists 
was identified for all the medicinal products excepting BYETTA. The pancreatic cancer was 
identified as risk for VICTOZA and TRULICITY; and other malignancies dose-related or not 
were addressed as safety concern for VICTOZA and LYXUMIA. 
As pancreatic cancer and thyroid neoplasms were the two major concerns regarding this 
SOC, the following analysis will be based on them.  
- Pancreatic cancer 
GLP-1R are abundantly expressed in the exocrine pancreas, and increased pancreatic 
weight has been observed, consistent with a trophic effect upon duct cells. A model has been 
proposed whereby proliferation of duct cells leads to localized duct occlusion and low-grade 
pancreatic inflammation, more typically manifest by subclinical increases in pancreatic 
enzymes, and more rarely in severe acute pancreatitis. The model further proposes that low 
grade inflammation and high levels of GLP-1 activity will predispose to the development of 
pancreatic cancer. Precancerous changes known as pancreatic intraepithelial neoplasia 
lesions precede the onset of pancreatic cancer, and are frequently present in the pancreas of 
middle-aged and elderly people and both pancreatic intraepithelial neoplasia lesions and 
pancreatic adenocarcinoma may carry the GLP-1R [58]. 
Moreover, pancreatitis presumably acts as a risk factor for subsequent pancreatic cancer 
through the mechanisms of chronic inflammation and increased cell turnover, it is not 
surprising that there is a progressive increased risk with years of exposure. For example, in 
patients with inherited chronic pancreatitis, the risk increases progressively with years of 
exposure, eventually reaching almost 75% [75, 76]. Once chronic pancreatitis has been 
established, chronic inflammation and enhanced intraductal pressure due to stenosis of the 
pancreatic duct(s) may lead to the development of pancreatic carcinoma. While this 
sequence is established in the case of chronic pancreatitis, it is not as certain whether an 
episode of acute pancreatitis will have the same consequences. The histological hallmarks of 
developing pancreatic carcinoma after chronic pancreatitis are pancreatic intraepithelial 
neoplasia, intraductal papillary mucinous neoplasms, and so-called pancreatic duct glands. 
The episodes of pancreatitis associated with GLP-1R agonist treatment seem to be episodes 
of acute pancreatitis [76]. 
As previously stated, in 2013, EMA was made aware of findings by a group of academic 
researchers suggesting an increased risk of pancreatitis and cellular changes in patients 
treated for T2DM with GLP-1 based therapies. The investigators described a number of 
findings in the pancreata of the T2DM individuals treated with these medicines which could 
implicated an association of the treatment with increased risk of pancreatitis and neoplasms 
[66]. Concerning pancreatic cancer, it was described that, in clinical trials, only single cases 
had been reported for some products and the duration of exposure was in the majority of the 
cases too short to support a causal relationship or to draw firm conclusions. The data 
available from clinical trials did not indicate an increased risk for pancreatic cancer with these 
medicines. In the post-marketing setting, cases of pancreatic cancer had been reported for 
most products, but in a rather large number of cases there were confounding factors or, in 
general, too short exposure to suspect a causal relationship with the products. It was noted 
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that MAHs were closely monitoring for effects on the pancreas. Long term consequences of 
stimulation of beta-cells and suppression of alpha cells as well as possible effects on 
exocrine pancreas were largely unknown and therefore some uncertainties existed. 
Considering that pancreatic cancers were very rare, large populations would need to be 
studied for a substantial duration to detect a possible increased risk. Observational studies 
had until that moment not been able to detect enough cases probably due to the rarity of the 
condition and, at least in Europe, rather low uptake of the products. Based on the above, the 
EMA concluded that pancreatic cancer must be included as a potential risk for all products 
for which it is not already reflected in the RMPs. Considering the low incidence of pancreatic 
cancer, results from the ongoing observational studies will also be of importance and 
therefore MAHs should ensure that pancreatic safety was adequately captured in these 
studies. Additionally, should new evidence indicate an increased risk of pancreatic cancer 
and/or a higher risk of pancreatitis compared to current estimations (e.g. from clinical studies 
and periodic safety update reports), the benefit-risk balance of GLP-1 based therapies 
should be re-evaluated [66]. 
- Thyroid neoplasms 
GLP-1R are expressed in thyroid tissue, especially in C cells. Exposure to long-acting GLP-
1R agonists has demonstrated an increase in thyroid C-cell hyperplasia, adenomas, and 
medullary thyroid carcinomas in mice, although not in humans. Rodent C-cells have 
considerably more GLP-1R than humans, which may explain the increase in some animal 
studies. Mice also develop thyroid C-cell carcinomas at much higher rates than humans, and 
increases have been observed even in mice treated with placebo. In general, medullary 
thyroid carcinoma in humans is very rare. Despite some reports have been identified for 
GLP-1R agonists, these cases are not sufficient to establish or to deny a causal association. 
[58, 59, 65].  
The signal of medullary thyroid cancer linked to long acting GLP-1R agonists (BYDUREON, 
VICTOZA, EPERZAN and TRULICITY) was evaluated by PRAC in 2015 [77]. Following 
labelling changes in the U.S. for long acting GLP-1R agonists (liraglutide, exenatide 
extended-release, albiglutide, and dulaglutide) to describe the first reported human cases of 
medullary thyroid cancer, a signal of medullary thyroid cancer was identified by the EMA 
during routine signal detection activities, based on 18 cases (including 16 for liraglutide only) 
retrieved from EudraVigilance. The PRAC discussed and concluded that medullary thyroid 
carcinoma is a potential risk in the RMP of long acting GLP-1R agonists and this safety 
concern is addressed in several ongoing studies. It was noted that the majority of cases were 
reported with liraglutide - including five cases in patients without a medical history of thyroid 
disorder or a family history of thyroid diseases, and that non-lethal thyroid C-cell tumours had 
been observed in the carcinogenicity studies. The PRAC agreed to request the MAH for 
liraglutide-containing products to provide a cumulative review of all cases concerning 
medullary thyroid cancer, both from clinical trials and spontaneously reported with liraglutide. 
Additionally, the MAH for VICTOZA should submit to the EMA a cumulative review of all 
cases of medullary thyroid cancer, both from clinical trials and spontaneous source reported 
with liraglutide-containing products. With this cumulative review, the MAH should also 
provide a discussion of relevant non-clinical data and scientific literature [77]. The MAH for 
VICTOZA replied to the request for information on the signal of medullary thyroid cancer. 
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Taking into account all the available evidence from post-marketing case reports, clinical 
trials, non-clinical data and the literature, the PRAC agreed that currently there is insufficient 
evidence to confirm a causal relationship between medullary thyroid cancer and liraglutide. 
Although non-clinical data suggested a mechanism for an increased risk of medullary thyroid 
cancer after liraglutide exposure, the available data in human use provides insufficient 
evidence to designate this as an identified risk. Because a causal relationship couldn’t be 
established, the PRAC considered that the current warning on thyroid cancers and the non-
clinical information with regard to observations in animals sufficiently reflect the currently 
available data regarding medullary thyroid cancer. Medullary thyroid cancer is already a 
potential risk in the RMP and should be continuously monitored and new relevant cases of 
medullary thyroid cancer should be presented and assessed in future PSURs for liraglutide 
[78].  
- Overall remarks referring to “real-world” data 
Referring to Table 20, of the present work, it is possible to realize that there are some 
discrepancies in the prevalence of this SOC between the oldest and the most recent 
medicines. For BYETTA and VICTOZA, which were the first GLP-1R agonists to hit the 
market, the SOC Neoplasms benign, malignant and unspecified occupies the 3rd and 2nd 
positions, respectively, in the ranking of the most prevalent SOCs. Otherwise, for LYXUMIA 
and TRULICITY this SOC occupies the 17th position of the ranking. This fact may be due to 
the long stay in the market of the firsts comparing to the last ones.  
It is interesting to observe what happens to this SOC in the Chart 11, which compares the 
prevalence of the SOCs of BYETTA and BYDUREON. As BYDUREON has been authorised 
several years after BYETTA this may influence the prevalence of occurrence of some ADRs 
(namely neoplasms). In the concerned chart, it is possible to see that the prevalence of 
Neoplasms benign, malignant and unspecified SOC is much lower with BYDUREON than 
with BYETTA.  
By the observation of the comparison charts of ADRs reported in the EU and in the U.S. 
(Chart 5, Chart 10 and Chart 18) it is possible to conclude that the prevalence of this 
concerned SOC is much higher in the EU than in the U.S., for that medicinal products. This is 
specially highlighted in the charts concerning BYETTA and VICTOZA, once in general the 
majority of the SOCs have much more number of reports in the U.S. than in the EU and the 
opposite happens with the Neoplasms benign, malignant and unspecified SOC.  
As regards in the PT charts presented for each medicinal product, BYDUREON, LYXUMIA 
and TRULICITY do not present any neoplasm-related PT in the top 35 of the mostly reported 
PTs, and the same occurred for BYETTA, BYDUREON and VICTOZA in the U.S. charts. 
Concerning BYETTA and VICTOZA EU charts, the PT pancreatic carcinoma occupies the 3rd 
and the 2nd places of the mostly reported ADRs, respectively. Beyond this, other PTs related 
to the occurrence of neoplasms are presented in the top 35 of the mostly reported ADRs for 
both medicinal products which are: pancreatic carcinoma metastatic (15th and 13th), 
metastases to liver (18th and 31st), thyroid cancer (23rd and 28th), adenocarcinoma pancreas 
(31st and 25th ) and papillary thyroid cancer (26th – for VICTOZA only).  
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Regarding the controversy of whether GLP-1–based therapy can increase the risk for 
specific malignant disease like pancreatic carcinoma and thyroid cancer, Nauck M et al, 
concludes that apparently there is neither firm evidence in favour of this hypothesis nor 
evidence strong enough to rule out any such increased risk based on results available at 
present [76]. Up to date, the FDA and the EMA have not reach a final conclusion regarding 
the possible association between the occurrence of cancers and the use of these medicinal 
products. FDA still recommends specific monitoring of medullary thyroid cancers in patients 
on GLP-1R agonists therapy [65]. 
 
On the basis of the aforementioned, it may be concluded that the nonclinical data are in 
accordance with the post-marketing information, as well as, to the assessments performed 
by the authorities. Regarding the pancreatic cancer, the only medicinal product for which this 
events was not considered a potential risk in the EU was VICTOZA. Nevertheless, and as 
identified, a thorough assessment was made and this medicine was specially evaluated, and 
as a consequence some updates were performed. Thus, probably the inclusion of pancreatic 
cancer as a safety concern was already made. Regarding medullary thyroid cancers, these 
are considered a potential risk for all medicinal products, therefore it is concluded that the 
safety concern is correctly addressed.  
 
NERVOUS SYSTEM DISORDERS SOC 
Terms that have a basis in a central nervous system disorder are linked primarily to SOC 
Nervous system disorders.  
Despite not having been identified as safety concern associated with this therapeutic class, 
the Nervous systems disorders SOC appears in the top 10 of the most prevalent SOCs for all 
the medicinal products both in the EU and in the U.S.. Comparing the EU and the U.S., in the 
U.S. this SOC was more prevalent in all applicable medicines than in the EU. Continuing the 
comparison, but now concerning to the exenatide-containing medicinal products, 
BYDUREON demonstrates a higher prevalence in this SOC than BYETTA.  
Among the 35 ADRs mostly reported, in the EU and/or in the U.S., it is possible to find some 
PTs concerning this SOC, for instance dizziness, headache, tremor and loss of 
consciousness.  
In the published literature it is stated that animal studies have demonstrated that agonists of 
the GLP-1R (for instance, liraglutide) were able to cross the blood brain barrier following 
peripheral administration, and peripheral administration of GLP-1 suppressed food intake 
over the dependent and independent pathways of the vagus nerve, resulting in direct action 
in the brain GLP-1R in the central nervous system [65, 79]. Therefore, the occurrence of 
events related to the SOC Nervous system disorders are expected.  
GLP-1R agonists have also been shown to exert a neuroprotective role in rodents with 
Alzheimer’s and Parkinson’s disease. Preclinical studies demonstrated that exendin-4 
decreased glutamate beta-amyloid peptide, preventing apoptosis in rat hippocampal neurons 
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in culture. Both glutamate and beta-amyloid peptide is involved in neurodegeneration 
process [65]. The incidences of Alzheimer’s disease and Parkinson’s disease are increased 
in people with T2DM, suggesting a relationship between neuronal cell death and insulin 
dysregulation. The presence of hippocampal atrophy is also increased in people with T2DM 
(compared with control subjects) and appears to be correlated with poor glycaemic control 
and marked glycaemic fluctuation. Use of GLP-1R agonist therapy in people with T2DM was 
negatively associated with hippocampal atrophy, suggesting that this approach may exert 
novel treatment possibilities for diabetic encephalopathy [79]. By limiting hippocampal 
atrophy in people with T2DM, it is suggested that GLP-1R agonists may prove to be a 
valuable therapeutic agent for the future treatment of neurodegenerative diseases. Large 
studies are currently underway to test the effect of liraglutide or exenatide treatment, both in 
comparison to placebo, on brain inflammation and neuronal damage in people with 
Alzheimer’s disease [79].  
 
RENAL AND URINARY DISORDERS SOC 
There is some evidence that GLP-1R agonists have a protective role in diabetic nephropathy. 
However, there are also associations of GLP-1R agonists with acute kidney injury. Exenatide 
is eliminated by renal mechanisms, and it is not recommended for use in patients with severe 
renal impairment or end-stage renal disease. In 2009, the FDA approved revisions to the 
drug label for exenatide to include information on post-marketing reports of altered kidney 
function. Main adverse effects of GLP-1R agonists include nausea and vomiting, which may 
result in decreased fluid intake and fluid loss, which can potentially lead to acute renal failure. 
Liraglutide is not eliminated renally, and mild renal impairment has not demonstrated a 
significant effect on its efficacy or safety, although there have been case reports of acute 
kidney injury with use of liraglutide in patients with moderate to severe renal impairment. 
Albiglutide once weekly was studied in a phase 3 trial compared to sitagliptin in patients with 
renal impairment and was found to be superior with similar tolerability. Of note, albiglutide 
does not require renal elimination or any dose adjustments for renal impairment. Dulaglutide 
also does not require any renal dose adjustments [58, 59, 65]. 
In the EU, acute renal failure/impairment was associated to the use of BYETTA, BYDUREON 
and LYXUMIA. For the first two this concern was classified as important identified risk and for 
the last one it was classified as important potential risk.  
In the U.S. renal impairment was also considered a safety concern for BYDUREON. For 
ADLYXIN the occurrence of renal impairment in patients with severe GI reactions is also 
considered a safety concern. Regarding TANZEUM and TRULICITY, the addressed risk 
corresponded to the worsening of renal function precipitated by dehydration due to product 
related GI adverse reactions.  
Concerning to the post-marketing data presented during this work, it is possible to observe 
that Renal and urinary disorders SOC has considerably high prevalence, as it is 
encompassed within the first 10 SOC mostly reported for all GLP-1R agonists, apart from 
BYDUREON and EPERZAN, for which there is no relevant post-marketing information.  
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As presented in Chart 11 and reflected in Table 20, Renal and urinary disorders SOC has 
major number of reports for BYETTA than for BYDUREON. 
Additionally, this SOC is most prevalent in the EU than in the U.S. for BYDUREON. In 
contrast, for VICTOZA and for BYETTA the major prevalence occurs in the U.S..  
Acute kidney injury and renal failure were the two PTs mostly reported related to this SOC. 
For Byetta both PTs were presented in the top 15 of the mostly reported ADRs in the EU, but 
not in the U.S.. TRULICITY also presented both PTs in the top 20 of the mostly reported 
ADRs, whereas LYXUMIA only presented acute kidney injury. BYDUREON did not 
presented any PT regarding this SOC among the top 35 of the mostly reported ADR.  
 
As observed above, renal conditions may be associated with the use of this therapeutic class 
medicinal products. This was identified in the pre-marketing phase and it was corroborated in 
the post-marketing.  
The most probable mechanism for this occurrence is nausea and vomiting, which if 
prolonged may result in dehydration, and severe dehydration leads to falling blood pressure, 
reduced perfusion of the kidneys and may cause acute renal failure. Those with 
compromised renal function, whether because of pre-existing vascular disease or because of 
a reduced number of functioning nephrons, are less able to compensate for acute 
dehydration, and are therefore at increased risk of acute renal failure [58].  
This safety concern is correctly addressed by all medicines, therefore no any other action 
might be suggested at this time.  
 
OTHER SAFETY CONCERNS 
Late stage microvascular eye complication is an important identified risk for VICTOZA, in the 
EU. However, the post-marketing the occurrence of eye-related conditions is low as well as 
the prevalence of the Eye disorders SOC.  
Teratogenicity is an important potential risk for LYXUMIA. Nevertheless, it is not corroborated 
by the post-marketing data, as no reports were identified in the SOC Congenital, familial and 
genetic disorders.  
EPERZAN presents pneumonia as important identified risk and hepatotoxicity and foetal and 
neonatal developmental toxicity as important potential risk. Nevertheless, no conclusion 
related to these risks may be provided as these risks were only identified for this medicinal 
product and no relevant post-marketing safety information is available for EPERZAN.  
 
LIMITATIONS 
During the elaboration of the present work, several limitations were detected and faced on.  
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The major limitation was to acquire post-marketing information related to the U.S. market, as 
no public databases are accessible now. The database used to elaborate the present work 
only provided data until the third quarter of 2012. Therefore, after this date no information 
regarding the post-marketing reports are presented. As TANZEUM, TRULICITY and 
ADLYXIN were only approved after 2013 regarding the U.S. market is presented for them. 
This situation did not allow a complete analysis and comparison between the EU and the 
U.S. reporting profile. Additionally, the information presented for BYETTA, VICTOZA and 
BYDUREON if also incomplete and the reporting profile could be changed since 2012.  
Other limitation was the absence of post-marketing data for EPERZAN in the EU database. 
As it was possible to see in the previous section, very scarce information was available for 
this medicinal product. Thus, it was not possible to make any conclusion regarding the 
reporting profile of this medicinal. Thus, it was not possible to know if the most reported 
ADRs in the post-marketing environment met those safety concerns identified in the pre-
marketing phase. Moreover, for this medicinal product pneumonia, hepatotoxicity and foetal 
and neonatal developmental toxicity were identified as safety concerns by the clinical 
studies. These concerns were not considered for any other medicinal product belonging to 
this therapeutic class, and so no conclusion was made regarding the prevalence of these 
risks.  
The data concerning the post-marketing reporting presented in the charts, in the RESULTS 
section, were collected from public databases which compiled the information of the total 
number of reported cases and presented them in chart and table format. One of the 
considered approaches was to try to normalize this data on the basis of total volume of sales, 
i.e. by the number of volume of sales it was possible to normalize the information per million 
of inhabitants, getting a more accurate basis for comparison of the occurrence of the 
reactions. Nonetheless, it was not possible to know the sales volume of such medicinal 
products and, thus, this normalization of data was not possible.  
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Conclusion/Final remarks  
The main goals of the present work were drawing a safety profile for GLP-1R agonist and 
conclude on the need and/or opportunity of adapting the RMP to the new markets. 
Throughout this process, it became clear that the occurrence of adverse reactions was 
associated both to the pharmaceutical formulation of the medicinal products and to their 
mechanism of action. In general, the adverse reactions were similar among all the medicinal 
products under evaluation. Ultimately, and although there are some areas of special concern 
which require further and thorough analysis (namely the occurrence of CV adverse effects 
and thyroid or pancreatic cancers), it was concluded that all the safety concerns are being 
very well monitored and followed either by the EMA/FDA or by the Marketing Authorisation 
Holders (MAHs). No additional minimisation measures, other than those already defined and 
implemented, seem to be necessary, and, therefore, the RMPs do not need to be updated. 
 
The GLP-1R are found throughout the body, including in the CV system, therefore providing 
a larger field to relevant metabolic influences such as diabetes and vascular complications. 
Specific receptors have been identified for G-protein coupled GLP-1 in tissues of the GI tract, 
pancreas, cardiac myocytes, liver, lung, blood vessels including the endothelium of the 
coronary artery, macrophages, peripheral nerves and the central nervous system [65]. 
GLP-1R agonists are effective agents for the treatment of T2DM, offering many advantages 
over other agents, including weight loss, potential β-cell protection and low risk of 
hypoglycaemia. They also have positive benefits on CV parameters, including reductions in 
blood pressure, lipids and body weight. Although long-term safety data is unavailable due to 
the short duration of time that these agents have been on the market, future studies will 
provide guidance to practitioners on the appropriate choice of agents to mitigate risk, 
including CV risk. Overall, GLP-1R agonists are effective and innovative agents for patients 
with T2DM and other chronic conditions, who are either uncontrolled or intolerant to first-line 
metformin therapy [59, 65, 79, 80]. 
Throughout the development of this project some limitations were detected. These limitations 
did not allow to perform a complete comparative analysis neither between the EU and the 
U.S. data, nor between all the medicinal products under analysis, as for EPERZAN no 
sufficient EU post-marketing data was available. Additionally, the normalization of the data 
presented in the charts was not possible as well.  
Despite the referred limitations, the following conclusions have high significance and they are 
also corroborated by the scientific published literature.  
In a global manner, the relevant safety information identified in the nonclinical phase was 
assessed and observed during the clinical phase. The results obtained from all the 
nonclinical and clinical studies were resumed in the RMP, in which the safety concerns were 
identified and classified as well as in which the plan for minimisation the risks is described. 
When observing the post-marketing data, collected from the public databases of adverse 
reactions reports, it was realized that, although some exceptions, the risks identified 
previously are the ones mostly reported.  
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In general, the safety concerns identified for each GLP-1R agonist are similar to the safety 
concerned identified to the others GLP-1R agonists. 
Regarding the European and the U.S. data several discrepancies were identified, namely 
what concerns to the malignancies occurrence. For example, in the post-marketing U.S. 
data, there was no cancer-related PTs reported within the top 35 of the mostly reported 
ADRs, whereas in the EU these reactions have high prevalence for some medicinal 
products.  
On what regards to the occurrence of the identified adverse reactions with the mechanism of 
action, it was possible to state that they were closely linked. The concerned effects occur in 
areas where GLP-1R exists.  
The occurrence of adverse reactions is also associated to the pharmaceutical formulation of 
the medicinal products, for instance long acting agents have more reports of injection site 
reactions.  
It's worth noting that some adverse events could be considered a beneficial outcome in some 
circumstances. This is what happens to the “rapid weight loss”, which was at the beginning 
identified as an identified risk for BYETTA and BYDUREON but not for the other medicines. 
This event had turned up into another indication for another medicinal product already 
approved for weight loss in patients without T2DM.  
There are some areas of special concern which require further and thorough analysis, 
namely the occurrence of CV adverse effects and thyroid or pancreatic cancers. However, all 
safety concerns are very well monitored and followed either by the EMA or by the MAHs, 
which have in project and in progress several safety studies to well characterise both the 
important risks and the missing information identified in the RMPs.  
As final conclusion, the safety profile of GLP-1R agonists remain unchanged after this 
evaluation and no new additional minimisation measures seems necessary.  
Moreover, GLP-1R agonists show broad metabolic effects, far beyond the glycaemic control, 
and represent effective therapies for T2DM. Further benefits on metabolism are being 
discovered, as new trials come out. The next few years are expected to bring relevant new 
data regarding extra glycaemic effects of GLP-1R agonists. [65]. 
  
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
 
ANDREIA FILIPA RODRIGUES DOS SANTOS Page 89  
References 
1. Prof. Dr. Iván Daío Sierra A., Dr. Carlos Olimpo Medivil A., and colaboradores, Diabetes 
Mellitus Tipo 2: Abordaje en el consultorio. 2009: Sierra Mendivil. 
2. Richard S. Beaser and Staff of Joslin Diabetes Center, Joslin's Diabetes Deskbook: A Guide for 
Primary Care Providers. Second updated ed. 2010: Joslin Diabetes Center. 
3. Anthony H. Barnett and Jenny Grice, Novos Mecanismos para o Controlo da Glicose. 1 ed. 
2012: Reza a História Edições. 
4. World Health Organization. Fact Sheets: Diabetes.  2015 January 2015 [cited 2015 
26/09/2015]; Available from: http://www.who.int/mediacentre/factsheets/fs312/en/. 
5. World Health Organization. Facts and figures: Diabetes Programme - Country and regional 
data on diabetes.  2015  [cited 2015 26/09/2015]; Available from: 
http://www.who.int/diabetes/facts/world_figures/en/. 
6. Sociedade Portuguesa de Diabetologia, Factos e Números o ano de 2015 - Relatório Anual do 
Observatório Nacional da Diabetes, edição de 2015. 2015. 
7. Stefan Silbernagl and Florian Lang, eds. Color Atlas of Pathophysiology. 2000, Thieme. 286-
293. 
8. Tim Holt and Sudhesh Kumar, ABC da Diabetes. 1 ed. 2010: Reza a História Edições. 
9. Eli Lilly (2011) BYDUREON - Risk Management Plan (Revision 14). 
10. H. P. Rang, et al., eds. Rang and Dale's Pharmacology. 6th Edition ed. 2008, Elsevier  
11. GlaxoSmithKline, European Union Risk Management Plan for EPERZAN. 2014. 
12. Berta Soldevila and Manel Puig-Domingo, Seguridad y tolerancia de los agonistas del receptor 
GLP-1. Med Clin, 2014. 143(Supl 2): p. 35-40. 
13. Jeffrey R. Unger and Christopher G. Parkin, Glucagon-Like Peptide-1 (GLP-1) Receptor 
Agonists: Differentiating the New Medications. Diabetes Ther, 2011. 2(1): p. 29-39. 
14. Jens Juul Holst, The Physiology of Glucagon-like Peptide 1. Physiol Rev, 2007. 87: p. 1409–
1439. 
15. Roman Vangoitsenhoven, Chantal Mathieu, and Bart Van der Schueren, GLP1 and cancer: 
friend or foe? Endocrine-Related Cancer, 2012. 19: p. F77-F88. 
16. Kristen Kulasa and Steven Edelman, Saxagliptin: the evidence for its place in the treatment of 
type 2 diabetes mellitus. Core Evid. , 2010. 5: p. 23-37. 
17. Véronique Gigoux and Daniel Fourmy, Acting on hormone receptors with minimal side effect 
on cell proliferation: a timely challenge illustrated with GLP-1R and GPER. Front. Endocrinol, 
2013. 4(50). 
18. Yumei Ye and Yochai Birnbaum, Cyclic AMP-mediated pleiotropic effects of glucagon-like 
peptide-1 receptor activation. Focus on “Exendin-4 attenuates high glucose-induced 
cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of 
SERCA2a”. Am J Physiol Cell Physiol, 2013. 304: p. C505-C507. 
19. Claire McDougall, Gerard A McKay, and Miles Fisher (2011) Drugs for Diabetes: Part 6 GLP-1 
Receptor Agonists. 18, 167-169. 
20. Tetsuhiro Tanaka, et al., The potential for renoprotection with incretin-based drugs. Kidney 
International, 2014. 86: p. 701-711. 
21. AstraZeneca AB (2011) Byetta Summay of Product Characteristics. 
22. EMA (2015) Byetta : EPAR - Product Information. 
23. AstraZeneca AB (2011) Bydureon Summary of Product Characteristics. 
24. Eli Lilly (2014) Victoza Summary of Product Characteristics. 
25. EMA (2012) Assessment report: Lyxumia. 
26. Sanofi-aventis groupe (2013) Lyxumia Summary of Product Characteristics. 
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
 
Page 90 ANDREIA FILIPA RODRIGUES DOS SANTOS 
27. EMA. EPAR summary for the public - Lyxumia.  2014  [cited 2015; Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/002445/WC500140450.pdf. 
28. CHMP (2014) Summary of opinion (initial athorisation) - Eperzan. 
29. GlaxoSmithKline (2014) Eperzan Summary of Product Characteristics. 
30. EMA (2014) Assessment report: Trulicity. 
31. Eli Lilly (2014) Trulicity Summary of Product Characteristics. 
32. PubMed. PubMed.gov - US National Library of Medicine National Institutes of Health. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed. 
33. NEJM. The New England Journal of Medicine. Available from: http://www.nejm.org/. 
34. EMA. European Public Assessment Reports. Available from: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&
mid=WC0b01ac058001d124. 
35. FDA. Drugs@FDA: FDA Approved Drug Products. Available from: 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. 
36. EudraVigilance. European database of suspected adverse drug reaction reports.   [cited 2015; 
Available from: http://www.adrreports.eu/en/index.html. 
37. DrugCite. DrugCite.com. Available from: http://www.drugcite.com/. 
38. Eli Lilly (2006) EU Risk Management Plan for Exenatide (AC2993, LY2148568) CHMP Day 180 
Response. 
39. Novo Nordisk A/S (2009) EU Risk Management Plan - Liraglutide/Type 2 diabetes. Edition 5. 
40. Eli Lilly (2014) EU Risk Management Plan - Trulicity. version 1.6. 
41. Sanofi-aventis Recherche et Développement, EU Risk Management Plan Lixisenatide 
(AVE0010). 2012. 
42. Lemos, F., Adverse Events/Mode of Action Relationship of Monoclonal Antibodies-Based 
Therapies: Overview of Marketed Products in the European Union. 2014, Universidade de 
Lisboa - Faculdade de Farmácia: Lisbon. p. 160. 
43. EMA (2006) Byetta: EPAR - Scientific Discussion. 
44. K. Eddie Gabry (2005) Byetta Medical Review (FDA) - Application Number: 21-773. 
45. EMA (2011) Assessment Report for Bydureon. 
46. Velerie S.W. Pratt (2011) Bydureon Medical Review (FDA) - Application Number: 22-200 SDN 
43. 
47. EMA (2009) Assessment Report for Victoza. 
48. FDA - Center for Drug Evaluation and Research (2010) Victoza Summary Review FDA - 
Application Number 22-341. 
49. CHMP (2012) Summary of opinion (initial authorisation) - Lyxumia. 
50. Jean-Marc Guettier (2016) Summary Review for Regulatory Action (FDA) - Application 
Number: 208471Orig1s000. 
51. CHMP (2014) Assessment report - Eperzan. 
52. FDA - Center for Drug Evaluation and Research, Tanzeum Summary Review - Application 
Number 124531Orig1s000. 2013. 
53. Kaveeta Vasisht, Tanzeum Medical Review (FDA) - Application Number 12543Orig1s000. 
2013. 
54. FDA - Center for Drug Evaluation and Research, Trulicity Summary Review - Application 
Number 125469Orig1s000. 2014. 
55. Suchitra Balakrishnan, Trulicity Medical Review (FDA) - Applocation Number 
125469Orig1s000. 2014. 
56. Francisco Kerr Saraiva and Andrei C Sposito, Cardiovascular effects of Glucagon-like peptide 1 
(GLP-1) receptor agonists. Cardiovascular Diabetology, 2014. 13(142). 
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
 
ANDREIA FILIPA RODRIGUES DOS SANTOS Page 91  
57. Ling Li, et al., Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: 
systematic review and meta-analysis of randomized and observational studies. BMC 
Cardiovascular Disorders, 2016. 16(91). 
58. Diapedia Collective. Safety of GLP-1 receptor agonists.  2014 August 13, 2014 [cited 2016 
November 22]; Available from: http://www.diapedia.org/81043351111/rev/18. 
59. Lalita Prasad-Reddy and Diana Isaacs, A clinical review of GLP-1 receptor agonists: efficacy 
and safety in diabetes and beyond. Drugs in Context, 2015. 4(212283.). 
60. Jennifer M. Trujillo, Wesley Nuffer, and Samuel L. Ellis, GLP-1 receptor agonists: a review of 
head-to-head clinical studies. Ther Adv Endocrinol Metab, 2015. 6(1): p. 19-28. 
61. American Diabetes Association. First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac 
Risk or Benefit.  2015 June 8, 2015 [cited 2016 21st November]; Available from: 
http://www.diabetes.org/newsroom/press-releases/2015/elixa.html. 
62. Robert J. Smith, Allison B. Goldfine, and William R. Hiatt, Evaluating the Cardiovascular Safety 
of New Medications for Type 2 Diabetes: Time to Reassess? Diabetes Care, 2016. 39: p. 738-
742. 
63. Feng Sun, et al., Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor 
Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. 
DIABETES TECHNOLOGY & THERAPEUTICS, 2015. 17(1): p. 35-42. 
64. Annachiara Uccellatore, et al., Comparison Review of Short-Acting and Long-Acting Glucagon-
like Peptide-1 Receptor Agonists. Diabetes Ther, 2015. 6: p. 239-256. 
65. Lis Marina de Mesquita Araújo, et al., Extra Glycemic Impacts of GLP-1 Receptor Agonists: 
Benefits of a Class Effect? Open Journal of Endocrine and Metabolic Diseases, 2016. 6: p. 43-
57. 
66. EMA (2013) Assessment report for GLP-1 based therapies - Procedure no: EMEA/H/A-
5(3)/1369. 
67. Zvonko Milicevic, et al., Low incidence of anti-drug antibodies in patients with type 2 diabetes 
treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes, 
Obesity and Metabolism, 2016. 18(5): p. 533-536. 
68. Anne Ottney, Glucagon-like peptide-1 receptor agonists for weight loss in adult patients 
without diabetes. Am J Health-Syst Pharm, 2013. 70: p. 2097-2103. 
69. M Rybicka , R Krysiak, and B Okopień, The dawn phenomenon and the Somogyi effect - two 
phenomena of morning hyperglycaemia. Endokrynol Pol., 2011. 62(3): p. 276-84. 
70. Geremia B. Bolli and John E. Gerich, The Dawn Phenomenon — A Common Occurrence in 
Both Non-Insulin-Dependent and Insulin-Dependent Diabetes Mellitus. New England Journal 
of Medicine, 1984. 310(12): p. 746-750. 
71. John P. Sheehan, Fasting Hyperglycemia: Etiology, Diagnosis, and Treatment. DIABETES 
TECHNOLOGY & THERAPEUTICS 
2004. 6(4): p. 525-533. 
72. P Choudhary, et al., Do high fasting glucose levels suggest nocturnal hypoglycaemia? The 
Somogyi effect-more fiction than fact? Diabet Med., 2013. 30(8): p. 914-7. 
73. P. De Feo, G. Perriello, and G. B. Bolli, Somogyi and Dawn Phenomena: Mechanisms. 
Diabeteshletabolism Reviews, 1988. 4(1): p. 31-49. 
74. Geremia B. Bolli, et al., Glucose Counterregulation and Waning of Insulin in the Somogyi 
Phenomenon (Posthypoglycemic Hyperglycemia). New England Journal of Medicine, 1984. 
311: p. 1214-9. 
75. Michael Elashoff, et al., Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like 
Peptide-1–Based Therapies. GASTROENTEROLOGY 2011. 141: p. 150-156. 
76. Michael A. Nauck and Nele Friedrich, Do GLP-1–Based Therapies Increase Cancer Risk? 
DIABETES CARE, 2013. 36(Suppl 2). 
MASTER’S DEGREE IN REGULATION AND EVALUATION OF MEDICINES AND HEALTH PRODUCTS: 
LESSONS LEARNED ON THE SAFETY OF GLP-1 RECEPTOR AGONISTS FROM POST-MARKETING EXPERIENCE 
 
Page 92 ANDREIA FILIPA RODRIGUES DOS SANTOS 
77. EMA (2015) Pharmacovigilance Risk Assessment Committee (PRAC) 
Minutes of the meeting on 04 - 07 May 2015. 
78. EMA (2015) Pharmacovigilance Risk Assessment Committee (PRAC)  
Minutes of the meeting on 07-10 September 2015. 
79. J. Seufert and B. Gallwitz, The extra-pancreatic effects of GLP-1 receptor agonists: a focus on 
the cardiovascular, gastrointestinal and central nervous systems. Diabetes, Obesity and 
Metabolism, 2014. 16: p. 673-688. 
80. André J Scheen, Cardiovascular safety of albiglutide and other glucagon-like peptide-1 
receptor agonists. Lancet Diabetes Endocrinol 2015. 3(9): p. p667–669. 
 
 
